{"transactions":[{"id":766446,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":16563,"kind":"person","name":"SCHULMAN AMY W","position":1,"cik":"0001438226","reported_name":"SCHULMAN AMY W","relationship":{"director":true}}],"security":"Stock Option  (Right to Buy)","published_at":"2026-05-22T20:18:46.000Z","date":"2026-05-20","kind":"grant","planned":false,"acquired":true,"shares":1802,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option will vest in full upon the earlier of the first anniversary of the grant date and the date of any earlier retirement or resignation of the Reporting Person, provided such date of retirement or resignation occurs no more than 90 days prior to the first anniversary of the grant date."}],"balance_after":1802,"derivative":{"exercise_price":298.48,"exercise_date":"2027-05-20","expiration_date":"2036-05-20","underlying":"Common Stock","underlying_shares":1802},"source":{"system":"sec-edgar","filing":"0001178670-26-000041","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000117867026000041/form4.xml","form_type":"4"}},{"id":766445,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":16563,"kind":"person","name":"SCHULMAN AMY W","position":1,"cik":"0001438226","reported_name":"SCHULMAN AMY W","relationship":{"director":true}}],"security":"Common Stock","published_at":"2026-05-22T20:18:46.000Z","date":"2026-05-20","kind":"grant","planned":false,"acquired":true,"shares":838,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares are represented by restricted stock units (RSUs) granted under the Second Amended and Restated 2018 Stock Incentive Plan. Each RSU represents a contingent right to receive one share of common stock. The RSUs will vest in full upon the earlier of the first anniversary of the grant date and the date of any earlier retirement or resignation of the Reporting Person, provided such date of retirement or resignation occurs no more than 90 days prior to the first anniversary of the grant date."}],"balance_after":24049,"source":{"system":"sec-edgar","filing":"0001178670-26-000041","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000117867026000041/form4.xml","form_type":"4"}},{"id":777522,"issuer":{"id":2934,"kind":"organization","name":"Elevance Health, Inc.","symbol":"ELV"},"owners":[{"id":16563,"kind":"person","name":"SCHULMAN AMY W","position":1,"cik":"0001438226","reported_name":"SCHULMAN AMY W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-05-15T20:16:22.000Z","date":"2026-05-13","kind":"grant","planned":false,"acquired":true,"shares":563,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Deferred stock units accrued under the Elevance Health, Inc. (\"Company\") Board of Directors Compensation Program."},{"field":"shares","element":"transactionShares","label":"F2","text":"The deferred stock units shall be payable in Company common stock upon the first to occur of (a) five years from the date of grant or (b) the date the Reporting Person ceases to be a member of the Company's board of directors, unless a later date is designated in the Reporting Person's election made under the Company's Board of Directors Deferred Compensation Plan."}],"balance_after":781,"source":{"system":"sec-edgar","filing":"0001438226-26-000009","document":"wk-form4_1778876180.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1156039/000143822626000009/wk-form4_1778876180.xml","form_type":"4"}},{"id":779549,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":16563,"kind":"person","name":"SCHULMAN AMY W","position":1,"cik":"0001438226","reported_name":"SCHULMAN AMY W","relationship":{"director":true}}],"security":"Stock Option  (Right to Buy)","published_at":"2026-05-14T20:17:02.000Z","date":"2026-05-13","kind":"exercise","planned":false,"acquired":false,"shares":11250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The options exercised and held by the reporting person were due to expire on June 3, 2026."}],"balance_after":0,"derivative":{"exercise_price":70.2,"exercise_date":"2017-06-03","expiration_date":"2026-06-03","underlying":"Common Stock","underlying_shares":11250},"source":{"system":"sec-edgar","filing":"0001178670-26-000017","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000117867026000017/form4.xml","form_type":"4"}},{"id":779548,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":16563,"kind":"person","name":"SCHULMAN AMY W","position":1,"cik":"0001438226","reported_name":"SCHULMAN AMY W","relationship":{"director":true}}],"security":"Common Stock","published_at":"2026-05-14T20:17:02.000Z","date":"2026-05-13","kind":"exercise","planned":false,"acquired":true,"shares":11250,"price":70.2,"value":789750.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The options exercised and held by the reporting person were due to expire on June 3, 2026."}],"balance_after":23211,"source":{"system":"sec-edgar","filing":"0001178670-26-000017","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000117867026000017/form4.xml","form_type":"4"}},{"id":831112,"issuer":{"id":2934,"kind":"organization","name":"Elevance Health, Inc.","symbol":"ELV"},"owners":[{"id":16563,"kind":"person","name":"SCHULMAN AMY W","position":1,"cik":"0001438226","reported_name":"SCHULMAN AMY W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-03-23T20:10:37.000Z","date":"2026-03-12","kind":"sale","planned":false,"acquired":false,"shares":26,"price":287.5,"value":7475.0,"ownership":{"direct":true},"balance_after":218,"source":{"system":"sec-edgar","filing":"0001438226-26-000007","document":"wk-form4_1774296634.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1156039/000143822626000007/wk-form4_1774296634.xml","form_type":"4"}},{"id":922486,"issuer":{"id":2934,"kind":"organization","name":"Elevance Health, Inc.","symbol":"ELV"},"owners":[{"id":16563,"kind":"person","name":"SCHULMAN AMY W","position":1,"cik":"0001438226","reported_name":"SCHULMAN AMY W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-02-03T21:42:37.000Z","date":"2026-02-02","kind":"grant","planned":false,"acquired":true,"shares":218,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Phantom Stock units accrued under the Elevance Health, Inc. (\"Company\") Board of Directors Compensation Program."},{"field":"shares","element":"transactionShares","label":"F2","text":"The phantom stock units shall be payable in Company common stock upon the first to occur of (a) five years from the date of the annual meeting of shareholders that immediately precedes the Director's election date or (b) the date the Reporting Person ceases to be a member of the Company's board of directors, unless a later date is designated in the Reporting Person's election made under the Company's Board of Directors Deferred Compensation Plan."}],"balance_after":218,"source":{"system":"sec-edgar","filing":"0001438226-26-000005","document":"wk-form4_1770154954.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1156039/000143822626000005/wk-form4_1770154954.xml","form_type":"4"}},{"id":1042731,"issuer":{"id":1161,"kind":"organization","name":"Camp4 Therapeutics Corp","symbol":"CAMP"},"owners":[{"id":75507,"kind":"organization","name":"Polaris Management Co. VII, L.L.C.","position":1,"cik":"0001678203","reported_name":"Polaris Management Co. VII, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":75508,"kind":"organization","name":"Polaris Partners VII, L.P.","position":2,"cik":"0001611189","reported_name":"Polaris Partners VII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":75509,"kind":"organization","name":"Polaris Entrepreneurs' Fund VII, L.P.","position":3,"cik":"0001615991","reported_name":"Polaris Entrepreneurs' Fund VII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":75510,"kind":"organization","name":"Polaris Partners X, L.P.","position":4,"cik":"0001910577","reported_name":"Polaris Partners X, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":75511,"kind":"organization","name":"Polaris Partners GP X, L.L.C.","position":5,"cik":"0001910575","reported_name":"Polaris Partners GP X, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":16563,"kind":"person","name":"SCHULMAN AMY W","position":6,"cik":"0001438226","reported_name":"SCHULMAN AMY W","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":75512,"kind":"person","name":"Chee Brian","position":7,"cik":"0001295675","reported_name":"Chee Brian","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-09-11T20:59:09.000Z","date":"2025-09-11","kind":"purchase","planned":false,"acquired":true,"shares":85468,"price":1.53,"value":130766.04,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On September 11, 2025, each of Polaris Partners VII, L.P. (\"PP VII\") and Polaris Entrepreneurs' Fund VII, L.P. (\"PEF VII\") acquired shares in a private placement by the Issuer pursuant to the terms of a Securities Purchase Agreement, dated as of September 9, 2025, by and among the Issuer and the investors party thereto at a purchase price of $1.53 per share."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The reported securities are owned directly by PEF VII. PMC VII is the general partner of PEF VII. Each of PMC VII and the PMC VII Managing Members in their respective capacities with respect to PMC VII, may be deemed to have shared voting, investment and dispositive power with respect to the securities held by PEF VII. Each of PMC VII and the PMC VII Managing Members disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of the PMC VII Managing Members or PMC VII is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein."}],"balance_after":197661,"source":{"system":"sec-edgar","filing":"0001193125-25-201392","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1438226/000119312525201392/ownership.xml","form_type":"4"}},{"id":1042730,"issuer":{"id":1161,"kind":"organization","name":"Camp4 Therapeutics Corp","symbol":"CAMP"},"owners":[{"id":75507,"kind":"organization","name":"Polaris Management Co. VII, L.L.C.","position":1,"cik":"0001678203","reported_name":"Polaris Management Co. VII, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":75508,"kind":"organization","name":"Polaris Partners VII, L.P.","position":2,"cik":"0001611189","reported_name":"Polaris Partners VII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":75509,"kind":"organization","name":"Polaris Entrepreneurs' Fund VII, L.P.","position":3,"cik":"0001615991","reported_name":"Polaris Entrepreneurs' Fund VII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":75510,"kind":"organization","name":"Polaris Partners X, L.P.","position":4,"cik":"0001910577","reported_name":"Polaris Partners X, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":75511,"kind":"organization","name":"Polaris Partners GP X, L.L.C.","position":5,"cik":"0001910575","reported_name":"Polaris Partners GP X, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":16563,"kind":"person","name":"SCHULMAN AMY W","position":6,"cik":"0001438226","reported_name":"SCHULMAN AMY W","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":75512,"kind":"person","name":"Chee Brian","position":7,"cik":"0001295675","reported_name":"Chee Brian","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-09-11T20:59:09.000Z","date":"2025-09-11","kind":"purchase","planned":false,"acquired":true,"shares":1221721,"price":1.53,"value":1869233.13,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On September 11, 2025, each of Polaris Partners VII, L.P. (\"PP VII\") and Polaris Entrepreneurs' Fund VII, L.P. (\"PEF VII\") acquired shares in a private placement by the Issuer pursuant to the terms of a Securities Purchase Agreement, dated as of September 9, 2025, by and among the Issuer and the investors party thereto at a purchase price of $1.53 per share."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The reported securities are owned directly by PP VII. Polaris Management Co. VII, L.L.C. (\"PMC VII\") is the general partner of PP VII. Each of David Barrett, Brian Chee, Amir Nashat, a member of the Issuer's board of directors, and Bryce Youngren (collectively, the \"PMC VII Managing Members\") are the managing members of PMC VII. Each of PMC VII and the PMC VII Managing Members in their respective capacities with respect to PMC VII, may be deemed to have shared voting, investment and dispositive power with respect to the securities held by PP VII. Each of PMC VII and the PMC VII Managing Members disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of the PMC VII Managing Members or PMC VII is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein."}],"balance_after":2825500,"source":{"system":"sec-edgar","filing":"0001193125-25-201392","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1438226/000119312525201392/ownership.xml","form_type":"4"}},{"id":1111464,"issuer":{"id":6700,"kind":"organization","name":"FRACTYL HEALTH, INC.","symbol":"GUTS"},"owners":[{"id":16563,"kind":"person","name":"SCHULMAN AMY W","position":1,"cik":"0001438226","reported_name":"SCHULMAN AMY W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option","published_at":"2025-06-13T20:05:22.000Z","date":"2025-06-11","kind":"grant","planned":false,"acquired":true,"shares":22500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option was awarded as compensation for the Reporting Person's service on the Issuer's board of directors pursuant to the Issuer's non-employee director compensation policy. The stock option will vest and become exercisable in a single installment on the earlier of (i) the date of the next annual meeting of stockholders or (ii) the first anniversary of the grant in each case subject to continued service on the Issuer's board of directors as a non-employee director through the vesting date."}],"balance_after":22500,"derivative":{"exercise_price":2.27,"expiration_date":"2035-06-10","underlying":"Common Stock","underlying_shares":22500},"source":{"system":"sec-edgar","filing":"0000950170-25-086148","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1438226/000095017025086148/ownership.xml","form_type":"4"}},{"id":1152510,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":16563,"kind":"person","name":"SCHULMAN AMY W","position":1,"cik":"0001438226","reported_name":"SCHULMAN AMY W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option  (right to buy)","published_at":"2025-05-12T20:04:39.000Z","date":"2025-05-08","kind":"grant","planned":false,"acquired":true,"shares":1558,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option vests in full upon the earlier of the first anniversary of the grant date and the date of any earlier retirement or resignation of the Reporting Person, provided such date of retirement or resignation occurs no more than 90 days prior to the first anniversary of the grant date."}],"balance_after":1558,"derivative":{"exercise_price":258.35,"exercise_date":"2026-05-08","expiration_date":"2035-05-08","underlying":"Common Stock","underlying_shares":1558},"source":{"system":"sec-edgar","filing":"0001735276-25-000061","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527625000061/edgardoc.xml","form_type":"4"}},{"id":1152509,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":16563,"kind":"person","name":"SCHULMAN AMY W","position":1,"cik":"0001438226","reported_name":"SCHULMAN AMY W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-05-12T20:04:39.000Z","date":"2025-05-08","kind":"grant","planned":false,"acquired":true,"shares":775,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares are represented by restricted stock units (RSUs) granted under the Amended and Restated 2018 Stock Incentive Plan. Each RSU represents a contingent right to receive one share of common stock. The RSUs will vest in full upon the earlier of the first anniversary of the grant date and the date of any earlier retirement or resignation of the Reporting Person, provided such date of retirement or resignation occurs no more than 90 days prior to the first anniversary of the grant date."}],"balance_after":11961,"source":{"system":"sec-edgar","filing":"0001735276-25-000061","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527625000061/edgardoc.xml","form_type":"4"}},{"id":1203651,"issuer":{"id":6700,"kind":"organization","name":"FRACTYL HEALTH, INC.","symbol":"GUTS"},"owners":[{"id":16563,"kind":"person","name":"SCHULMAN AMY W","position":1,"cik":"0001438226","reported_name":"SCHULMAN AMY W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-03-17T21:09:08.000Z","date":"2025-03-13","kind":"purchase","planned":false,"acquired":true,"shares":8550,"price":1.1654,"value":9964.17,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from 1.165 to 1.17, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote."}],"balance_after":8550,"source":{"system":"sec-edgar","filing":"0000950170-25-040466","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1438226/000095017025040466/ownership.xml","form_type":"4"}},{"id":1206005,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":16563,"kind":"person","name":"SCHULMAN AMY W","position":1,"cik":"0001438226","reported_name":"SCHULMAN AMY W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option  (right to buy)","published_at":"2025-03-14T20:16:13.000Z","date":"2025-03-13","kind":"exercise","planned":false,"acquired":false,"shares":2750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The options exercised and held by the reporting person were due to expire on June 1, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option was fully vested as of June 1, 2016."}],"balance_after":0,"derivative":{"exercise_price":131.21,"exercise_date":"2016-06-01","expiration_date":"2025-06-01","underlying":"Common Stock","underlying_shares":2750},"source":{"system":"sec-edgar","filing":"0001735276-25-000037","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527625000037/edgardoc.xml","form_type":"4"}},{"id":1206004,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":16563,"kind":"person","name":"SCHULMAN AMY W","position":1,"cik":"0001438226","reported_name":"SCHULMAN AMY W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-03-14T20:16:13.000Z","date":"2025-03-13","kind":"exercise","planned":false,"acquired":true,"shares":2750,"price":131.21,"value":360827.5,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The options exercised and held by the reporting person were due to expire on June 1, 2025."}],"balance_after":11186,"source":{"system":"sec-edgar","filing":"0001735276-25-000037","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527625000037/edgardoc.xml","form_type":"4"}},{"id":1382865,"issuer":{"id":1161,"kind":"organization","name":"Camp4 Therapeutics Corp","symbol":"CAMP"},"owners":[{"id":75507,"kind":"organization","name":"Polaris Management Co. VII, L.L.C.","position":1,"cik":"0001678203","reported_name":"Polaris Management Co. VII, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":75508,"kind":"organization","name":"Polaris Partners VII, L.P.","position":2,"cik":"0001611189","reported_name":"Polaris Partners VII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":75509,"kind":"organization","name":"Polaris Entrepreneurs' Fund VII, L.P.","position":3,"cik":"0001615991","reported_name":"Polaris Entrepreneurs' Fund VII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":75510,"kind":"organization","name":"Polaris Partners X, L.P.","position":4,"cik":"0001910577","reported_name":"Polaris Partners X, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":75511,"kind":"organization","name":"Polaris Partners GP X, L.L.C.","position":5,"cik":"0001910575","reported_name":"Polaris Partners GP X, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":16563,"kind":"person","name":"SCHULMAN AMY W","position":6,"cik":"0001438226","reported_name":"SCHULMAN AMY W","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":75512,"kind":"person","name":"Chee Brian","position":7,"cik":"0001295675","reported_name":"Chee Brian","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Preferred Stock","published_at":"2024-10-22T21:31:39.000Z","date":"2024-10-15","kind":"exercise","planned":false,"acquired":false,"shares":277536,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"On October 15, 2024, the shares of Series B Preferred Stock automatically converted into shares of Common Stock on a 11.2158-for-one basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"On October 15, 2024, the shares of Series B Preferred Stock automatically converted into shares of Common Stock on a 11.2158-for-one basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"On October 15, 2024, the shares of Series B Preferred Stock automatically converted into shares of Common Stock on a 11.2158-for-one basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"On October 15, 2024, the shares of Series B Preferred Stock automatically converted into shares of Common Stock on a 11.2158-for-one basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The reported securities are owned directly by Polaris Entrepreneurs' Fund VII, L.P. (\"PEF VII\"). PMC VII is the general partner of PEF VII. Each of PMC VII and the PMC VII Managing Members in their respective capacities with respect to PMC VII, may be deemed to have shared voting, investment and dispositive power with respect to the securities held by PEF VII.  Each of PMC VII and the PMC VII Managing Members disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of the PMC VII Managing Members or PMC VII is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":24745},"source":{"system":"sec-edgar","filing":"0000950170-24-116360","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1438226/000095017024116360/ownership.xml","form_type":"4/A","original_submission_date":"2024-10-15"}},{"id":1382864,"issuer":{"id":1161,"kind":"organization","name":"Camp4 Therapeutics Corp","symbol":"CAMP"},"owners":[{"id":75507,"kind":"organization","name":"Polaris Management Co. VII, L.L.C.","position":1,"cik":"0001678203","reported_name":"Polaris Management Co. VII, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":75508,"kind":"organization","name":"Polaris Partners VII, L.P.","position":2,"cik":"0001611189","reported_name":"Polaris Partners VII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":75509,"kind":"organization","name":"Polaris Entrepreneurs' Fund VII, L.P.","position":3,"cik":"0001615991","reported_name":"Polaris Entrepreneurs' Fund VII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":75510,"kind":"organization","name":"Polaris Partners X, L.P.","position":4,"cik":"0001910577","reported_name":"Polaris Partners X, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":75511,"kind":"organization","name":"Polaris Partners GP X, L.L.C.","position":5,"cik":"0001910575","reported_name":"Polaris Partners GP X, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":16563,"kind":"person","name":"SCHULMAN AMY W","position":6,"cik":"0001438226","reported_name":"SCHULMAN AMY W","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":75512,"kind":"person","name":"Chee Brian","position":7,"cik":"0001295675","reported_name":"Chee Brian","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Preferred Stock","published_at":"2024-10-22T21:31:39.000Z","date":"2024-10-15","kind":"exercise","planned":false,"acquired":false,"shares":3967234,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"On October 15, 2024, the shares of Series B Preferred Stock automatically converted into shares of Common Stock on a 11.2158-for-one basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"On October 15, 2024, the shares of Series B Preferred Stock automatically converted into shares of Common Stock on a 11.2158-for-one basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"On October 15, 2024, the shares of Series B Preferred Stock automatically converted into shares of Common Stock on a 11.2158-for-one basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"On October 15, 2024, the shares of Series B Preferred Stock automatically converted into shares of Common Stock on a 11.2158-for-one basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The reported securities are owned directly by Polaris Partners VII, L.P. (\"PP VII\"). Polaris Management Co. VII, L.L.C. (\"PMC VII\") is the general partner of PP VII. Each of David Barrett, Brian Chee, Amir Nashat, a member of the Issuer's board of directors, and Bryce Youngren (collectively, the \"PMC VII Managing Members\") are the managing members of PMC VII. Each of PMC VII and the PMC VII Managing Members in their respective capacities with respect to PMC VII, may be deemed to have shared voting, investment and dispositive power with respect to the securities held by PP VII.  Each of PMC VII and the PMC VII Managing Members disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of the PMC VII Managing Members or PMC VII is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":353718},"source":{"system":"sec-edgar","filing":"0000950170-24-116360","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1438226/000095017024116360/ownership.xml","form_type":"4/A","original_submission_date":"2024-10-15"}},{"id":1382863,"issuer":{"id":1161,"kind":"organization","name":"Camp4 Therapeutics Corp","symbol":"CAMP"},"owners":[{"id":75507,"kind":"organization","name":"Polaris Management Co. VII, L.L.C.","position":1,"cik":"0001678203","reported_name":"Polaris Management Co. VII, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":75508,"kind":"organization","name":"Polaris Partners VII, L.P.","position":2,"cik":"0001611189","reported_name":"Polaris Partners VII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":75509,"kind":"organization","name":"Polaris Entrepreneurs' Fund VII, L.P.","position":3,"cik":"0001615991","reported_name":"Polaris Entrepreneurs' Fund VII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":75510,"kind":"organization","name":"Polaris Partners X, L.P.","position":4,"cik":"0001910577","reported_name":"Polaris Partners X, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":75511,"kind":"organization","name":"Polaris Partners GP X, L.L.C.","position":5,"cik":"0001910575","reported_name":"Polaris Partners GP X, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":16563,"kind":"person","name":"SCHULMAN AMY W","position":6,"cik":"0001438226","reported_name":"SCHULMAN AMY W","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":75512,"kind":"person","name":"Chee Brian","position":7,"cik":"0001295675","reported_name":"Chee Brian","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Prime Preferred Stock","published_at":"2024-10-22T21:31:39.000Z","date":"2024-10-15","kind":"exercise","planned":false,"acquired":false,"shares":980829,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"On October 15, 2024, the shares of Series A Prime Convertible Preferred Stock automatically converted into shares of Common Stock on a 11.2158-for-one basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On October 15, 2024, the shares of Series A Prime Convertible Preferred Stock automatically converted into shares of Common Stock on a 11.2158-for-one basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On October 15, 2024, the shares of Series A Prime Convertible Preferred Stock automatically converted into shares of Common Stock on a 11.2158-for-one basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"On October 15, 2024, the shares of Series A Prime Convertible Preferred Stock automatically converted into shares of Common Stock on a 11.2158-for-one basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The reported securities are owned directly by Polaris Entrepreneurs' Fund VII, L.P. (\"PEF VII\"). PMC VII is the general partner of PEF VII. Each of PMC VII and the PMC VII Managing Members in their respective capacities with respect to PMC VII, may be deemed to have shared voting, investment and dispositive power with respect to the securities held by PEF VII.  Each of PMC VII and the PMC VII Managing Members disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of the PMC VII Managing Members or PMC VII is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":87448},"source":{"system":"sec-edgar","filing":"0000950170-24-116360","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1438226/000095017024116360/ownership.xml","form_type":"4/A","original_submission_date":"2024-10-15"}},{"id":1382862,"issuer":{"id":1161,"kind":"organization","name":"Camp4 Therapeutics Corp","symbol":"CAMP"},"owners":[{"id":75507,"kind":"organization","name":"Polaris Management Co. VII, L.L.C.","position":1,"cik":"0001678203","reported_name":"Polaris Management Co. VII, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":75508,"kind":"organization","name":"Polaris Partners VII, L.P.","position":2,"cik":"0001611189","reported_name":"Polaris Partners VII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":75509,"kind":"organization","name":"Polaris Entrepreneurs' Fund VII, L.P.","position":3,"cik":"0001615991","reported_name":"Polaris Entrepreneurs' Fund VII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":75510,"kind":"organization","name":"Polaris Partners X, L.P.","position":4,"cik":"0001910577","reported_name":"Polaris Partners X, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":75511,"kind":"organization","name":"Polaris Partners GP X, L.L.C.","position":5,"cik":"0001910575","reported_name":"Polaris Partners GP X, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":16563,"kind":"person","name":"SCHULMAN AMY W","position":6,"cik":"0001438226","reported_name":"SCHULMAN AMY W","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":75512,"kind":"person","name":"Chee Brian","position":7,"cik":"0001295675","reported_name":"Chee Brian","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Prime Preferred Stock","published_at":"2024-10-22T21:31:39.000Z","date":"2024-10-15","kind":"exercise","planned":false,"acquired":false,"shares":14020475,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"On October 15, 2024, the shares of Series A Prime Convertible Preferred Stock automatically converted into shares of Common Stock on a 11.2158-for-one basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On October 15, 2024, the shares of Series A Prime Convertible Preferred Stock automatically converted into shares of Common Stock on a 11.2158-for-one basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On October 15, 2024, the shares of Series A Prime Convertible Preferred Stock automatically converted into shares of Common Stock on a 11.2158-for-one basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"On October 15, 2024, the shares of Series A Prime Convertible Preferred Stock automatically converted into shares of Common Stock on a 11.2158-for-one basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The reported securities are owned directly by Polaris Partners VII, L.P. (\"PP VII\"). Polaris Management Co. VII, L.L.C. (\"PMC VII\") is the general partner of PP VII. Each of David Barrett, Brian Chee, Amir Nashat, a member of the Issuer's board of directors, and Bryce Youngren (collectively, the \"PMC VII Managing Members\") are the managing members of PMC VII. Each of PMC VII and the PMC VII Managing Members in their respective capacities with respect to PMC VII, may be deemed to have shared voting, investment and dispositive power with respect to the securities held by PP VII.  Each of PMC VII and the PMC VII Managing Members disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of the PMC VII Managing Members or PMC VII is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1250061},"source":{"system":"sec-edgar","filing":"0000950170-24-116360","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1438226/000095017024116360/ownership.xml","form_type":"4/A","original_submission_date":"2024-10-15"}},{"id":1382861,"issuer":{"id":1161,"kind":"organization","name":"Camp4 Therapeutics Corp","symbol":"CAMP"},"owners":[{"id":75507,"kind":"organization","name":"Polaris Management Co. VII, L.L.C.","position":1,"cik":"0001678203","reported_name":"Polaris Management Co. VII, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":75508,"kind":"organization","name":"Polaris Partners VII, L.P.","position":2,"cik":"0001611189","reported_name":"Polaris Partners VII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":75509,"kind":"organization","name":"Polaris Entrepreneurs' Fund VII, L.P.","position":3,"cik":"0001615991","reported_name":"Polaris Entrepreneurs' Fund VII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":75510,"kind":"organization","name":"Polaris Partners X, L.P.","position":4,"cik":"0001910577","reported_name":"Polaris Partners X, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":75511,"kind":"organization","name":"Polaris Partners GP X, L.L.C.","position":5,"cik":"0001910575","reported_name":"Polaris Partners GP X, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":16563,"kind":"person","name":"SCHULMAN AMY W","position":6,"cik":"0001438226","reported_name":"SCHULMAN AMY W","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":75512,"kind":"person","name":"Chee Brian","position":7,"cik":"0001295675","reported_name":"Chee Brian","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-10-22T21:31:39.000Z","date":"2024-10-15","kind":"purchase","planned":false,"acquired":true,"shares":909090,"price":11,"value":9999990.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"The reported securities are owned directly by Polaris Partners X, L.P. (\"PP X\"). Polaris Partners GP X, L.L.C. (\"PPGP X\") is the general partner of PP X. Each of Amy Schulman and Brian Chee are the managing members of PPGP X (the \"PPGP X Managing Members\"). Amir Nashat (\"Mr. Nashat\"), a member of the Issuer's board of directors, is an interest holder of PPGP X. Each of PPGP X, the PPGP X Managing Members and Mr. Nashat, in their respective capacities with respect to PPGP X, may be deemed to have shared voting, investment and dispositive power with respect to the securities held by PP X.  Each of PPGP X, the PPGP X Managing Members and Mr. Nashat disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of the PPGP X Managing Members, Mr. Nashat or PPGP X is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein."}],"balance_after":909090,"source":{"system":"sec-edgar","filing":"0000950170-24-116360","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1438226/000095017024116360/ownership.xml","form_type":"4/A","original_submission_date":"2024-10-15"}},{"id":1382860,"issuer":{"id":1161,"kind":"organization","name":"Camp4 Therapeutics Corp","symbol":"CAMP"},"owners":[{"id":75507,"kind":"organization","name":"Polaris Management Co. VII, L.L.C.","position":1,"cik":"0001678203","reported_name":"Polaris Management Co. VII, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":75508,"kind":"organization","name":"Polaris Partners VII, L.P.","position":2,"cik":"0001611189","reported_name":"Polaris Partners VII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":75509,"kind":"organization","name":"Polaris Entrepreneurs' Fund VII, L.P.","position":3,"cik":"0001615991","reported_name":"Polaris Entrepreneurs' Fund VII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":75510,"kind":"organization","name":"Polaris Partners X, L.P.","position":4,"cik":"0001910577","reported_name":"Polaris Partners X, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":75511,"kind":"organization","name":"Polaris Partners GP X, L.L.C.","position":5,"cik":"0001910575","reported_name":"Polaris Partners GP X, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":16563,"kind":"person","name":"SCHULMAN AMY W","position":6,"cik":"0001438226","reported_name":"SCHULMAN AMY W","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":75512,"kind":"person","name":"Chee Brian","position":7,"cik":"0001295675","reported_name":"Chee Brian","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-10-22T21:31:39.000Z","date":"2024-10-15","kind":"exercise","planned":false,"acquired":true,"shares":24745,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"On October 15, 2024, the shares of Series B Preferred Stock automatically converted into shares of Common Stock on a 11.2158-for-one basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"On October 15, 2024, the shares of Series B Preferred Stock automatically converted into shares of Common Stock on a 11.2158-for-one basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The reported securities are owned directly by Polaris Entrepreneurs' Fund VII, L.P. (\"PEF VII\"). PMC VII is the general partner of PEF VII. Each of PMC VII and the PMC VII Managing Members in their respective capacities with respect to PMC VII, may be deemed to have shared voting, investment and dispositive power with respect to the securities held by PEF VII.  Each of PMC VII and the PMC VII Managing Members disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of the PMC VII Managing Members or PMC VII is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein."}],"balance_after":112193,"source":{"system":"sec-edgar","filing":"0000950170-24-116360","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1438226/000095017024116360/ownership.xml","form_type":"4/A","original_submission_date":"2024-10-15"}},{"id":1382859,"issuer":{"id":1161,"kind":"organization","name":"Camp4 Therapeutics Corp","symbol":"CAMP"},"owners":[{"id":75507,"kind":"organization","name":"Polaris Management Co. VII, L.L.C.","position":1,"cik":"0001678203","reported_name":"Polaris Management Co. VII, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":75508,"kind":"organization","name":"Polaris Partners VII, L.P.","position":2,"cik":"0001611189","reported_name":"Polaris Partners VII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":75509,"kind":"organization","name":"Polaris Entrepreneurs' Fund VII, L.P.","position":3,"cik":"0001615991","reported_name":"Polaris Entrepreneurs' Fund VII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":75510,"kind":"organization","name":"Polaris Partners X, L.P.","position":4,"cik":"0001910577","reported_name":"Polaris Partners X, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":75511,"kind":"organization","name":"Polaris Partners GP X, L.L.C.","position":5,"cik":"0001910575","reported_name":"Polaris Partners GP X, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":16563,"kind":"person","name":"SCHULMAN AMY W","position":6,"cik":"0001438226","reported_name":"SCHULMAN AMY W","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":75512,"kind":"person","name":"Chee Brian","position":7,"cik":"0001295675","reported_name":"Chee Brian","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-10-22T21:31:39.000Z","date":"2024-10-15","kind":"exercise","planned":false,"acquired":true,"shares":353718,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"On October 15, 2024, the shares of Series B Preferred Stock automatically converted into shares of Common Stock on a 11.2158-for-one basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"On October 15, 2024, the shares of Series B Preferred Stock automatically converted into shares of Common Stock on a 11.2158-for-one basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The reported securities are owned directly by Polaris Partners VII, L.P. (\"PP VII\"). Polaris Management Co. VII, L.L.C. (\"PMC VII\") is the general partner of PP VII. Each of David Barrett, Brian Chee, Amir Nashat, a member of the Issuer's board of directors, and Bryce Youngren (collectively, the \"PMC VII Managing Members\") are the managing members of PMC VII. Each of PMC VII and the PMC VII Managing Members in their respective capacities with respect to PMC VII, may be deemed to have shared voting, investment and dispositive power with respect to the securities held by PP VII.  Each of PMC VII and the PMC VII Managing Members disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of the PMC VII Managing Members or PMC VII is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein."}],"balance_after":1603779,"source":{"system":"sec-edgar","filing":"0000950170-24-116360","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1438226/000095017024116360/ownership.xml","form_type":"4/A","original_submission_date":"2024-10-15"}},{"id":1382858,"issuer":{"id":1161,"kind":"organization","name":"Camp4 Therapeutics Corp","symbol":"CAMP"},"owners":[{"id":75507,"kind":"organization","name":"Polaris Management Co. VII, L.L.C.","position":1,"cik":"0001678203","reported_name":"Polaris Management Co. VII, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":75508,"kind":"organization","name":"Polaris Partners VII, L.P.","position":2,"cik":"0001611189","reported_name":"Polaris Partners VII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":75509,"kind":"organization","name":"Polaris Entrepreneurs' Fund VII, L.P.","position":3,"cik":"0001615991","reported_name":"Polaris Entrepreneurs' Fund VII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":75510,"kind":"organization","name":"Polaris Partners X, L.P.","position":4,"cik":"0001910577","reported_name":"Polaris Partners X, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":75511,"kind":"organization","name":"Polaris Partners GP X, L.L.C.","position":5,"cik":"0001910575","reported_name":"Polaris Partners GP X, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":16563,"kind":"person","name":"SCHULMAN AMY W","position":6,"cik":"0001438226","reported_name":"SCHULMAN AMY W","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":75512,"kind":"person","name":"Chee Brian","position":7,"cik":"0001295675","reported_name":"Chee Brian","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-10-22T21:31:39.000Z","date":"2024-10-15","kind":"exercise","planned":false,"acquired":true,"shares":87448,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On October 15, 2024, the shares of Series A Prime Convertible Preferred Stock automatically converted into shares of Common Stock on a 11.2158-for-one basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On October 15, 2024, the shares of Series A Prime Convertible Preferred Stock automatically converted into shares of Common Stock on a 11.2158-for-one basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The reported securities are owned directly by Polaris Entrepreneurs' Fund VII, L.P. (\"PEF VII\"). PMC VII is the general partner of PEF VII. Each of PMC VII and the PMC VII Managing Members in their respective capacities with respect to PMC VII, may be deemed to have shared voting, investment and dispositive power with respect to the securities held by PEF VII.  Each of PMC VII and the PMC VII Managing Members disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of the PMC VII Managing Members or PMC VII is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein."}],"balance_after":87448,"source":{"system":"sec-edgar","filing":"0000950170-24-116360","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1438226/000095017024116360/ownership.xml","form_type":"4/A","original_submission_date":"2024-10-15"}},{"id":1382857,"issuer":{"id":1161,"kind":"organization","name":"Camp4 Therapeutics Corp","symbol":"CAMP"},"owners":[{"id":75507,"kind":"organization","name":"Polaris Management Co. VII, L.L.C.","position":1,"cik":"0001678203","reported_name":"Polaris Management Co. VII, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":75508,"kind":"organization","name":"Polaris Partners VII, L.P.","position":2,"cik":"0001611189","reported_name":"Polaris Partners VII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":75509,"kind":"organization","name":"Polaris Entrepreneurs' Fund VII, L.P.","position":3,"cik":"0001615991","reported_name":"Polaris Entrepreneurs' Fund VII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":75510,"kind":"organization","name":"Polaris Partners X, L.P.","position":4,"cik":"0001910577","reported_name":"Polaris Partners X, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":75511,"kind":"organization","name":"Polaris Partners GP X, L.L.C.","position":5,"cik":"0001910575","reported_name":"Polaris Partners GP X, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":16563,"kind":"person","name":"SCHULMAN AMY W","position":6,"cik":"0001438226","reported_name":"SCHULMAN AMY W","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":75512,"kind":"person","name":"Chee Brian","position":7,"cik":"0001295675","reported_name":"Chee Brian","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-10-22T21:31:39.000Z","date":"2024-10-15","kind":"exercise","planned":false,"acquired":true,"shares":1250061,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On October 15, 2024, the shares of Series A Prime Convertible Preferred Stock automatically converted into shares of Common Stock on a 11.2158-for-one basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On October 15, 2024, the shares of Series A Prime Convertible Preferred Stock automatically converted into shares of Common Stock on a 11.2158-for-one basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The reported securities are owned directly by Polaris Partners VII, L.P. (\"PP VII\"). Polaris Management Co. VII, L.L.C. (\"PMC VII\") is the general partner of PP VII. Each of David Barrett, Brian Chee, Amir Nashat, a member of the Issuer's board of directors, and Bryce Youngren (collectively, the \"PMC VII Managing Members\") are the managing members of PMC VII. Each of PMC VII and the PMC VII Managing Members in their respective capacities with respect to PMC VII, may be deemed to have shared voting, investment and dispositive power with respect to the securities held by PP VII.  Each of PMC VII and the PMC VII Managing Members disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of the PMC VII Managing Members or PMC VII is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein."}],"balance_after":1250061,"source":{"system":"sec-edgar","filing":"0000950170-24-116360","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1438226/000095017024116360/ownership.xml","form_type":"4/A","original_submission_date":"2024-10-15"}},{"id":1386643,"issuer":{"id":1161,"kind":"organization","name":"Camp4 Therapeutics Corp","symbol":"CAMP"},"owners":[{"id":75507,"kind":"organization","name":"Polaris Management Co. VII, L.L.C.","position":1,"cik":"0001678203","reported_name":"Polaris Management Co. VII, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":75508,"kind":"organization","name":"Polaris Partners VII, L.P.","position":2,"cik":"0001611189","reported_name":"Polaris Partners VII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":75509,"kind":"organization","name":"Polaris Entrepreneurs' Fund VII, L.P.","position":3,"cik":"0001615991","reported_name":"Polaris Entrepreneurs' Fund VII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":75510,"kind":"organization","name":"Polaris Partners X, L.P.","position":4,"cik":"0001910577","reported_name":"Polaris Partners X, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":75511,"kind":"organization","name":"Polaris Partners GP X, L.L.C.","position":5,"cik":"0001910575","reported_name":"Polaris Partners GP X, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":16563,"kind":"person","name":"SCHULMAN AMY W","position":6,"cik":"0001438226","reported_name":"SCHULMAN AMY W","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Preferred Stock","published_at":"2024-10-15T22:00:16.000Z","date":"2024-10-15","kind":"exercise","planned":false,"acquired":false,"shares":277536,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"On October 15, 2024, the shares of Series B Preferred Stock automatically converted into shares of Common Stock on a 11.2158-for-one basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"On October 15, 2024, the shares of Series B Preferred Stock automatically converted into shares of Common Stock on a 11.2158-for-one basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"On October 15, 2024, the shares of Series B Preferred Stock automatically converted into shares of Common Stock on a 11.2158-for-one basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"On October 15, 2024, the shares of Series B Preferred Stock automatically converted into shares of Common Stock on a 11.2158-for-one basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The reported securities are owned directly by Polaris Entrepreneurs' Fund VII, L.P. (\"PEF VII\"). PMC VII is the general partner of PEF VII. Each of PMC VII and the PMC VII Managing Members in their respective capacities with respect to PMC VII, may be deemed to have shared voting, investment and dispositive power with respect to the securities held by PEF VII.  Each of PMC VII and the PMC VII Managing Members disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of the PMC VII Managing Members or PMC VII is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":24745},"source":{"system":"sec-edgar","filing":"0000950170-24-114788","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1438226/000095017024114788/ownership.xml","form_type":"4"}},{"id":1386642,"issuer":{"id":1161,"kind":"organization","name":"Camp4 Therapeutics Corp","symbol":"CAMP"},"owners":[{"id":75507,"kind":"organization","name":"Polaris Management Co. VII, L.L.C.","position":1,"cik":"0001678203","reported_name":"Polaris Management Co. VII, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":75508,"kind":"organization","name":"Polaris Partners VII, L.P.","position":2,"cik":"0001611189","reported_name":"Polaris Partners VII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":75509,"kind":"organization","name":"Polaris Entrepreneurs' Fund VII, L.P.","position":3,"cik":"0001615991","reported_name":"Polaris Entrepreneurs' Fund VII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":75510,"kind":"organization","name":"Polaris Partners X, L.P.","position":4,"cik":"0001910577","reported_name":"Polaris Partners X, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":75511,"kind":"organization","name":"Polaris Partners GP X, L.L.C.","position":5,"cik":"0001910575","reported_name":"Polaris Partners GP X, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":16563,"kind":"person","name":"SCHULMAN AMY W","position":6,"cik":"0001438226","reported_name":"SCHULMAN AMY W","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Preferred Stock","published_at":"2024-10-15T22:00:16.000Z","date":"2024-10-15","kind":"exercise","planned":false,"acquired":false,"shares":3967234,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"On October 15, 2024, the shares of Series B Preferred Stock automatically converted into shares of Common Stock on a 11.2158-for-one basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"On October 15, 2024, the shares of Series B Preferred Stock automatically converted into shares of Common Stock on a 11.2158-for-one basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"On October 15, 2024, the shares of Series B Preferred Stock automatically converted into shares of Common Stock on a 11.2158-for-one basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"On October 15, 2024, the shares of Series B Preferred Stock automatically converted into shares of Common Stock on a 11.2158-for-one basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The reported securities are owned directly by Polaris Partners VII, L.P. (\"PP VII\"). Polaris Management Co. VII, L.L.C. (\"PMC VII\") is the general partner of PP VII. Each of David Barrett, Brian Chee, Amir Nashat, a member of the Issuer's board of directors, and Bryce Youngren (collectively, the \"PMC VII Managing Members\") are the managing members of PMC VII. Each of PMC VII and the PMC VII Managing Members in their respective capacities with respect to PMC VII, may be deemed to have shared voting, investment and dispositive power with respect to the securities held by PP VII.  Each of PMC VII and the PMC VII Managing Members disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of the PMC VII Managing Members or PMC VII is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":353718},"source":{"system":"sec-edgar","filing":"0000950170-24-114788","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1438226/000095017024114788/ownership.xml","form_type":"4"}},{"id":1386641,"issuer":{"id":1161,"kind":"organization","name":"Camp4 Therapeutics Corp","symbol":"CAMP"},"owners":[{"id":75507,"kind":"organization","name":"Polaris Management Co. VII, L.L.C.","position":1,"cik":"0001678203","reported_name":"Polaris Management Co. VII, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":75508,"kind":"organization","name":"Polaris Partners VII, L.P.","position":2,"cik":"0001611189","reported_name":"Polaris Partners VII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":75509,"kind":"organization","name":"Polaris Entrepreneurs' Fund VII, L.P.","position":3,"cik":"0001615991","reported_name":"Polaris Entrepreneurs' Fund VII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":75510,"kind":"organization","name":"Polaris Partners X, L.P.","position":4,"cik":"0001910577","reported_name":"Polaris Partners X, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":75511,"kind":"organization","name":"Polaris Partners GP X, L.L.C.","position":5,"cik":"0001910575","reported_name":"Polaris Partners GP X, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":16563,"kind":"person","name":"SCHULMAN AMY W","position":6,"cik":"0001438226","reported_name":"SCHULMAN AMY W","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Prime Preferred Stock","published_at":"2024-10-15T22:00:16.000Z","date":"2024-10-15","kind":"exercise","planned":false,"acquired":false,"shares":980829,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"On October 15, 2024, the shares of Series A Prime Convertible Preferred Stock automatically converted into shares of Common Stock on a 11.2158-for-one basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On October 15, 2024, the shares of Series A Prime Convertible Preferred Stock automatically converted into shares of Common Stock on a 11.2158-for-one basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On October 15, 2024, the shares of Series A Prime Convertible Preferred Stock automatically converted into shares of Common Stock on a 11.2158-for-one basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"On October 15, 2024, the shares of Series A Prime Convertible Preferred Stock automatically converted into shares of Common Stock on a 11.2158-for-one basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The reported securities are owned directly by Polaris Entrepreneurs' Fund VII, L.P. (\"PEF VII\"). PMC VII is the general partner of PEF VII. Each of PMC VII and the PMC VII Managing Members in their respective capacities with respect to PMC VII, may be deemed to have shared voting, investment and dispositive power with respect to the securities held by PEF VII.  Each of PMC VII and the PMC VII Managing Members disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of the PMC VII Managing Members or PMC VII is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":87448},"source":{"system":"sec-edgar","filing":"0000950170-24-114788","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1438226/000095017024114788/ownership.xml","form_type":"4"}},{"id":1386640,"issuer":{"id":1161,"kind":"organization","name":"Camp4 Therapeutics Corp","symbol":"CAMP"},"owners":[{"id":75507,"kind":"organization","name":"Polaris Management Co. VII, L.L.C.","position":1,"cik":"0001678203","reported_name":"Polaris Management Co. VII, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":75508,"kind":"organization","name":"Polaris Partners VII, L.P.","position":2,"cik":"0001611189","reported_name":"Polaris Partners VII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":75509,"kind":"organization","name":"Polaris Entrepreneurs' Fund VII, L.P.","position":3,"cik":"0001615991","reported_name":"Polaris Entrepreneurs' Fund VII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":75510,"kind":"organization","name":"Polaris Partners X, L.P.","position":4,"cik":"0001910577","reported_name":"Polaris Partners X, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":75511,"kind":"organization","name":"Polaris Partners GP X, L.L.C.","position":5,"cik":"0001910575","reported_name":"Polaris Partners GP X, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":16563,"kind":"person","name":"SCHULMAN AMY W","position":6,"cik":"0001438226","reported_name":"SCHULMAN AMY W","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Prime Preferred Stock","published_at":"2024-10-15T22:00:16.000Z","date":"2024-10-15","kind":"exercise","planned":false,"acquired":false,"shares":14020475,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"On October 15, 2024, the shares of Series A Prime Convertible Preferred Stock automatically converted into shares of Common Stock on a 11.2158-for-one basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On October 15, 2024, the shares of Series A Prime Convertible Preferred Stock automatically converted into shares of Common Stock on a 11.2158-for-one basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On October 15, 2024, the shares of Series A Prime Convertible Preferred Stock automatically converted into shares of Common Stock on a 11.2158-for-one basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"On October 15, 2024, the shares of Series A Prime Convertible Preferred Stock automatically converted into shares of Common Stock on a 11.2158-for-one basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The reported securities are owned directly by Polaris Partners VII, L.P. (\"PP VII\"). Polaris Management Co. VII, L.L.C. (\"PMC VII\") is the general partner of PP VII. Each of David Barrett, Brian Chee, Amir Nashat, a member of the Issuer's board of directors, and Bryce Youngren (collectively, the \"PMC VII Managing Members\") are the managing members of PMC VII. Each of PMC VII and the PMC VII Managing Members in their respective capacities with respect to PMC VII, may be deemed to have shared voting, investment and dispositive power with respect to the securities held by PP VII.  Each of PMC VII and the PMC VII Managing Members disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of the PMC VII Managing Members or PMC VII is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1250061},"source":{"system":"sec-edgar","filing":"0000950170-24-114788","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1438226/000095017024114788/ownership.xml","form_type":"4"}},{"id":1386639,"issuer":{"id":1161,"kind":"organization","name":"Camp4 Therapeutics Corp","symbol":"CAMP"},"owners":[{"id":75507,"kind":"organization","name":"Polaris Management Co. VII, L.L.C.","position":1,"cik":"0001678203","reported_name":"Polaris Management Co. VII, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":75508,"kind":"organization","name":"Polaris Partners VII, L.P.","position":2,"cik":"0001611189","reported_name":"Polaris Partners VII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":75509,"kind":"organization","name":"Polaris Entrepreneurs' Fund VII, L.P.","position":3,"cik":"0001615991","reported_name":"Polaris Entrepreneurs' Fund VII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":75510,"kind":"organization","name":"Polaris Partners X, L.P.","position":4,"cik":"0001910577","reported_name":"Polaris Partners X, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":75511,"kind":"organization","name":"Polaris Partners GP X, L.L.C.","position":5,"cik":"0001910575","reported_name":"Polaris Partners GP X, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":16563,"kind":"person","name":"SCHULMAN AMY W","position":6,"cik":"0001438226","reported_name":"SCHULMAN AMY W","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-10-15T22:00:16.000Z","date":"2024-10-15","kind":"purchase","planned":false,"acquired":true,"shares":909090,"price":11,"value":9999990.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"The reported securities are owned directly by Polaris Partners X, L.P. (\"PP X\"). Polaris Partners GP X, L.L.C. (\"PPGP X\") is the general partner of PP X. Each of Amy Schulman and Brian Chee are the managing members of PPGP X (the \"PPGP X Managing Members\"). Amir Nashat (\"Mr. Nashat\"), a member of the Issuer's board of directors, is an interest holder of PPGP X. Each of PPGP X, the PPGP X Managing Members and Mr. Nashat, in their respective capacities with respect to PPGP X, may be deemed to have shared voting, investment and dispositive power with respect to the securities held by PP X.  Each of PPGP X, the PPGP X Managing Members and Mr. Nashat disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of the PPGP X Managing Members, Mr. Nashat or PPGP X is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein."}],"balance_after":909090,"source":{"system":"sec-edgar","filing":"0000950170-24-114788","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1438226/000095017024114788/ownership.xml","form_type":"4"}},{"id":1386638,"issuer":{"id":1161,"kind":"organization","name":"Camp4 Therapeutics Corp","symbol":"CAMP"},"owners":[{"id":75507,"kind":"organization","name":"Polaris Management Co. VII, L.L.C.","position":1,"cik":"0001678203","reported_name":"Polaris Management Co. VII, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":75508,"kind":"organization","name":"Polaris Partners VII, L.P.","position":2,"cik":"0001611189","reported_name":"Polaris Partners VII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":75509,"kind":"organization","name":"Polaris Entrepreneurs' Fund VII, L.P.","position":3,"cik":"0001615991","reported_name":"Polaris Entrepreneurs' Fund VII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":75510,"kind":"organization","name":"Polaris Partners X, L.P.","position":4,"cik":"0001910577","reported_name":"Polaris Partners X, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":75511,"kind":"organization","name":"Polaris Partners GP X, L.L.C.","position":5,"cik":"0001910575","reported_name":"Polaris Partners GP X, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":16563,"kind":"person","name":"SCHULMAN AMY W","position":6,"cik":"0001438226","reported_name":"SCHULMAN AMY W","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-10-15T22:00:16.000Z","date":"2024-10-15","kind":"exercise","planned":false,"acquired":true,"shares":24745,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"On October 15, 2024, the shares of Series B Preferred Stock automatically converted into shares of Common Stock on a 11.2158-for-one basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"On October 15, 2024, the shares of Series B Preferred Stock automatically converted into shares of Common Stock on a 11.2158-for-one basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The reported securities are owned directly by Polaris Entrepreneurs' Fund VII, L.P. (\"PEF VII\"). PMC VII is the general partner of PEF VII. Each of PMC VII and the PMC VII Managing Members in their respective capacities with respect to PMC VII, may be deemed to have shared voting, investment and dispositive power with respect to the securities held by PEF VII.  Each of PMC VII and the PMC VII Managing Members disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of the PMC VII Managing Members or PMC VII is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein."}],"balance_after":112193,"source":{"system":"sec-edgar","filing":"0000950170-24-114788","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1438226/000095017024114788/ownership.xml","form_type":"4"}},{"id":1386637,"issuer":{"id":1161,"kind":"organization","name":"Camp4 Therapeutics Corp","symbol":"CAMP"},"owners":[{"id":75507,"kind":"organization","name":"Polaris Management Co. VII, L.L.C.","position":1,"cik":"0001678203","reported_name":"Polaris Management Co. VII, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":75508,"kind":"organization","name":"Polaris Partners VII, L.P.","position":2,"cik":"0001611189","reported_name":"Polaris Partners VII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":75509,"kind":"organization","name":"Polaris Entrepreneurs' Fund VII, L.P.","position":3,"cik":"0001615991","reported_name":"Polaris Entrepreneurs' Fund VII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":75510,"kind":"organization","name":"Polaris Partners X, L.P.","position":4,"cik":"0001910577","reported_name":"Polaris Partners X, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":75511,"kind":"organization","name":"Polaris Partners GP X, L.L.C.","position":5,"cik":"0001910575","reported_name":"Polaris Partners GP X, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":16563,"kind":"person","name":"SCHULMAN AMY W","position":6,"cik":"0001438226","reported_name":"SCHULMAN AMY W","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-10-15T22:00:16.000Z","date":"2024-10-15","kind":"exercise","planned":false,"acquired":true,"shares":353718,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"On October 15, 2024, the shares of Series B Preferred Stock automatically converted into shares of Common Stock on a 11.2158-for-one basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"On October 15, 2024, the shares of Series B Preferred Stock automatically converted into shares of Common Stock on a 11.2158-for-one basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The reported securities are owned directly by Polaris Partners VII, L.P. (\"PP VII\"). Polaris Management Co. VII, L.L.C. (\"PMC VII\") is the general partner of PP VII. Each of David Barrett, Brian Chee, Amir Nashat, a member of the Issuer's board of directors, and Bryce Youngren (collectively, the \"PMC VII Managing Members\") are the managing members of PMC VII. Each of PMC VII and the PMC VII Managing Members in their respective capacities with respect to PMC VII, may be deemed to have shared voting, investment and dispositive power with respect to the securities held by PP VII.  Each of PMC VII and the PMC VII Managing Members disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of the PMC VII Managing Members or PMC VII is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein."}],"balance_after":1603779,"source":{"system":"sec-edgar","filing":"0000950170-24-114788","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1438226/000095017024114788/ownership.xml","form_type":"4"}},{"id":1386636,"issuer":{"id":1161,"kind":"organization","name":"Camp4 Therapeutics Corp","symbol":"CAMP"},"owners":[{"id":75507,"kind":"organization","name":"Polaris Management Co. VII, L.L.C.","position":1,"cik":"0001678203","reported_name":"Polaris Management Co. VII, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":75508,"kind":"organization","name":"Polaris Partners VII, L.P.","position":2,"cik":"0001611189","reported_name":"Polaris Partners VII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":75509,"kind":"organization","name":"Polaris Entrepreneurs' Fund VII, L.P.","position":3,"cik":"0001615991","reported_name":"Polaris Entrepreneurs' Fund VII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":75510,"kind":"organization","name":"Polaris Partners X, L.P.","position":4,"cik":"0001910577","reported_name":"Polaris Partners X, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":75511,"kind":"organization","name":"Polaris Partners GP X, L.L.C.","position":5,"cik":"0001910575","reported_name":"Polaris Partners GP X, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":16563,"kind":"person","name":"SCHULMAN AMY W","position":6,"cik":"0001438226","reported_name":"SCHULMAN AMY W","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-10-15T22:00:16.000Z","date":"2024-10-15","kind":"exercise","planned":false,"acquired":true,"shares":87448,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On October 15, 2024, the shares of Series A Prime Convertible Preferred Stock automatically converted into shares of Common Stock on a 11.2158-for-one basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On October 15, 2024, the shares of Series A Prime Convertible Preferred Stock automatically converted into shares of Common Stock on a 11.2158-for-one basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The reported securities are owned directly by Polaris Entrepreneurs' Fund VII, L.P. (\"PEF VII\"). PMC VII is the general partner of PEF VII. Each of PMC VII and the PMC VII Managing Members in their respective capacities with respect to PMC VII, may be deemed to have shared voting, investment and dispositive power with respect to the securities held by PEF VII.  Each of PMC VII and the PMC VII Managing Members disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of the PMC VII Managing Members or PMC VII is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein."}],"balance_after":87448,"source":{"system":"sec-edgar","filing":"0000950170-24-114788","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1438226/000095017024114788/ownership.xml","form_type":"4"}},{"id":1386635,"issuer":{"id":1161,"kind":"organization","name":"Camp4 Therapeutics Corp","symbol":"CAMP"},"owners":[{"id":75507,"kind":"organization","name":"Polaris Management Co. VII, L.L.C.","position":1,"cik":"0001678203","reported_name":"Polaris Management Co. VII, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":75508,"kind":"organization","name":"Polaris Partners VII, L.P.","position":2,"cik":"0001611189","reported_name":"Polaris Partners VII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":75509,"kind":"organization","name":"Polaris Entrepreneurs' Fund VII, L.P.","position":3,"cik":"0001615991","reported_name":"Polaris Entrepreneurs' Fund VII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":75510,"kind":"organization","name":"Polaris Partners X, L.P.","position":4,"cik":"0001910577","reported_name":"Polaris Partners X, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":75511,"kind":"organization","name":"Polaris Partners GP X, L.L.C.","position":5,"cik":"0001910575","reported_name":"Polaris Partners GP X, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":16563,"kind":"person","name":"SCHULMAN AMY W","position":6,"cik":"0001438226","reported_name":"SCHULMAN AMY W","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-10-15T22:00:16.000Z","date":"2024-10-15","kind":"exercise","planned":false,"acquired":true,"shares":1250061,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On October 15, 2024, the shares of Series A Prime Convertible Preferred Stock automatically converted into shares of Common Stock on a 11.2158-for-one basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On October 15, 2024, the shares of Series A Prime Convertible Preferred Stock automatically converted into shares of Common Stock on a 11.2158-for-one basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The reported securities are owned directly by Polaris Partners VII, L.P. (\"PP VII\"). Polaris Management Co. VII, L.L.C. (\"PMC VII\") is the general partner of PP VII. Each of David Barrett, Brian Chee, Amir Nashat, a member of the Issuer's board of directors, and Bryce Youngren (collectively, the \"PMC VII Managing Members\") are the managing members of PMC VII. Each of PMC VII and the PMC VII Managing Members in their respective capacities with respect to PMC VII, may be deemed to have shared voting, investment and dispositive power with respect to the securities held by PP VII.  Each of PMC VII and the PMC VII Managing Members disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of the PMC VII Managing Members or PMC VII is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein."}],"balance_after":1250061,"source":{"system":"sec-edgar","filing":"0000950170-24-114788","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1438226/000095017024114788/ownership.xml","form_type":"4"}},{"id":1468288,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":16563,"kind":"person","name":"SCHULMAN AMY W","position":1,"cik":"0001438226","reported_name":"SCHULMAN AMY W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option  (right to buy)","published_at":"2024-06-27T20:04:53.000Z","date":"2024-06-25","kind":"exercise","planned":true,"acquired":false,"shares":8500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"All transactions reported on this Form 4 were made pursuant to a Rule 10b5-1(c) trading plan adopted by the reporting person on February 28, 2024."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This stock option was fully vested and exercisable as of June 1, 2016."}],"balance_after":2750,"derivative":{"exercise_price":131.21,"exercise_date":"2016-06-01","expiration_date":"2025-06-01","underlying":"Common Stock","underlying_shares":8500},"source":{"system":"sec-edgar","filing":"0001735276-24-000072","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527624000072/edgardoc.xml","form_type":"4"}},{"id":1468287,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":16563,"kind":"person","name":"SCHULMAN AMY W","position":1,"cik":"0001438226","reported_name":"SCHULMAN AMY W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-06-27T20:04:53.000Z","date":"2024-06-25","kind":"sale","planned":true,"acquired":false,"shares":8500,"price":240,"value":2040000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"All transactions reported on this Form 4 were made pursuant to a Rule 10b5-1(c) trading plan adopted by the reporting person on February 28, 2024."}],"balance_after":8436,"source":{"system":"sec-edgar","filing":"0001735276-24-000072","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527624000072/edgardoc.xml","form_type":"4"}},{"id":1468286,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":16563,"kind":"person","name":"SCHULMAN AMY W","position":1,"cik":"0001438226","reported_name":"SCHULMAN AMY W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-06-27T20:04:53.000Z","date":"2024-06-25","kind":"exercise","planned":true,"acquired":true,"shares":8500,"price":131.21,"value":1115285.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"All transactions reported on this Form 4 were made pursuant to a Rule 10b5-1(c) trading plan adopted by the reporting person on February 28, 2024."}],"balance_after":16936,"source":{"system":"sec-edgar","filing":"0001735276-24-000072","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527624000072/edgardoc.xml","form_type":"4"}},{"id":1496882,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":16563,"kind":"person","name":"SCHULMAN AMY W","position":1,"cik":"0001438226","reported_name":"SCHULMAN AMY W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option  (right to buy)","published_at":"2024-05-31T23:00:52.000Z","date":"2024-05-29","kind":"exercise","planned":true,"acquired":false,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Reflects shares sold to cover option cost and tax obligations upon the option exercise pursuant to a Rule 10b5-1(c) trading plan adopted by the reporting person on February 28, 2024. The 30,000 options exercised by the reporting person were due to expire on July 1, 2024."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"This stock option was fully vested and exercisable as of July 1, 2017."}],"balance_after":0,"derivative":{"exercise_price":66.83,"expiration_date":"2024-07-01","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001735276-24-000058","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527624000058/edgardoc.xml","form_type":"4"}},{"id":1496881,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":16563,"kind":"person","name":"SCHULMAN AMY W","position":1,"cik":"0001438226","reported_name":"SCHULMAN AMY W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-05-31T23:00:52.000Z","date":"2024-05-29","kind":"sale","planned":true,"acquired":false,"shares":63,"price":149.76,"value":9434.88,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Reflects shares sold to cover option cost and tax obligations upon the option exercise pursuant to a Rule 10b5-1(c) trading plan adopted by the reporting person on February 28, 2024. The 30,000 options exercised by the reporting person were due to expire on July 1, 2024."}],"balance_after":8436,"source":{"system":"sec-edgar","filing":"0001735276-24-000058","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527624000058/edgardoc.xml","form_type":"4"}},{"id":1496880,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":16563,"kind":"person","name":"SCHULMAN AMY W","position":1,"cik":"0001438226","reported_name":"SCHULMAN AMY W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-05-31T23:00:52.000Z","date":"2024-05-29","kind":"sale","planned":true,"acquired":false,"shares":11516,"price":148.93,"value":1715077.88,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Reflects shares sold to cover option cost and tax obligations upon the option exercise pursuant to a Rule 10b5-1(c) trading plan adopted by the reporting person on February 28, 2024. The 30,000 options exercised by the reporting person were due to expire on July 1, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $148.63 to $149.52. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":8499,"source":{"system":"sec-edgar","filing":"0001735276-24-000058","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527624000058/edgardoc.xml","form_type":"4"}},{"id":1496879,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":16563,"kind":"person","name":"SCHULMAN AMY W","position":1,"cik":"0001438226","reported_name":"SCHULMAN AMY W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-05-31T23:00:52.000Z","date":"2024-05-29","kind":"sale","planned":true,"acquired":false,"shares":10121,"price":148.21,"value":1500033.41,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Reflects shares sold to cover option cost and tax obligations upon the option exercise pursuant to a Rule 10b5-1(c) trading plan adopted by the reporting person on February 28, 2024. The 30,000 options exercised by the reporting person were due to expire on July 1, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $147.62 to $148.60. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":20015,"source":{"system":"sec-edgar","filing":"0001735276-24-000058","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527624000058/edgardoc.xml","form_type":"4"}},{"id":1496878,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":16563,"kind":"person","name":"SCHULMAN AMY W","position":1,"cik":"0001438226","reported_name":"SCHULMAN AMY W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-05-31T23:00:52.000Z","date":"2024-05-29","kind":"exercise","planned":true,"acquired":true,"shares":30000,"price":66.83,"value":2004900.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Reflects shares sold to cover option cost and tax obligations upon the option exercise pursuant to a Rule 10b5-1(c) trading plan adopted by the reporting person on February 28, 2024. The 30,000 options exercised by the reporting person were due to expire on July 1, 2024."}],"balance_after":30136,"source":{"system":"sec-edgar","filing":"0001735276-24-000058","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527624000058/edgardoc.xml","form_type":"4"}},{"id":1509302,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":16563,"kind":"person","name":"SCHULMAN AMY W","position":1,"cik":"0001438226","reported_name":"SCHULMAN AMY W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option  (right to buy)","published_at":"2024-05-20T20:04:11.000Z","date":"2024-05-16","kind":"grant","planned":false,"acquired":true,"shares":5228,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This award vests in full upon the earlier of the first anniversary of the grant date and the date of any earlier retirement or resignation of the Reporting Person, provided such date of retirement or resignation occurs no more than 90 days prior to the first anniversary of the grant date."}],"balance_after":5228,"derivative":{"exercise_price":151.22,"exercise_date":"2025-05-16","expiration_date":"2034-05-16","underlying":"Common Stock","underlying_shares":5228},"source":{"system":"sec-edgar","filing":"0001735276-24-000047","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527624000047/edgardoc.xml","form_type":"4"}},{"id":1658635,"issuer":{"id":6700,"kind":"organization","name":"FRACTYL HEALTH, INC.","symbol":"GUTS"},"owners":[{"id":16563,"kind":"person","name":"SCHULMAN AMY W","position":1,"cik":"0001438226","reported_name":"SCHULMAN AMY W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option","published_at":"2024-02-05T22:05:19.000Z","date":"2024-02-01","kind":"grant","planned":false,"acquired":true,"shares":45000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests in three annual installments beginning on February 1, 2025."}],"balance_after":45000,"derivative":{"exercise_price":15,"expiration_date":"2034-01-31","underlying":"Common Stock","underlying_shares":45000},"source":{"system":"sec-edgar","filing":"0000950170-24-011323","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1438226/000095017024011323/ownership.xml","form_type":"4"}},{"id":1854205,"issuer":{"id":112267,"kind":"organization","name":"SQZ Biotechnologies Co","symbol":"SQZ"},"owners":[{"id":16563,"kind":"person","name":"SCHULMAN AMY W","position":1,"cik":"0001438226","reported_name":"SCHULMAN AMY W","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option","published_at":"2023-06-15T20:46:40.000Z","date":"2023-06-14","kind":"grant","planned":false,"acquired":true,"shares":39875,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests and become exercisable on the earlier of (i) June 14, 2024 or (ii) the day immediately prior to the date of the next annual meeting of stockholders following the date of grant, in each case subject to the recipient's continued service on the Board at such time."}],"balance_after":39875,"derivative":{"exercise_price":0.539,"expiration_date":"2033-06-13","underlying":"Common Stock","underlying_shares":39875},"source":{"system":"sec-edgar","filing":"0001209191-23-037386","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1438226/000120919123037386/doc4.xml","form_type":"4"}},{"id":1885133,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":16563,"kind":"person","name":"SCHULMAN AMY W","position":1,"cik":"0001438226","reported_name":"SCHULMAN AMY W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option  (right to buy)","published_at":"2023-05-19T20:04:55.000Z","date":"2023-05-18","kind":"grant","planned":false,"acquired":true,"shares":3454,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This award vests in full upon the earlier of the first anniversary of the grant date and the date of any earlier retirement or resignation of the Reporting Person, provided such date of retirement or resignation occurs no more than 90 days prior to the first anniversary of the grant date."}],"balance_after":3454,"derivative":{"exercise_price":189.87,"exercise_date":"2024-05-18","expiration_date":"2033-05-18","underlying":"Common Stock","underlying_shares":3454},"source":{"system":"sec-edgar","filing":"0001735276-23-000063","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527623000063/edgardoc.xml","form_type":"4"}},{"id":1990715,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":16563,"kind":"person","name":"SCHULMAN AMY W","position":1,"cik":"0001438226","reported_name":"SCHULMAN AMY W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2023-02-27T21:13:50.000Z","date":"2023-02-23","kind":"exercise","acquired":false,"shares":136,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of ALNY common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This award vested on February 23, 2023, the first anniversary of the grant date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"This award vested on February 23, 2023, the first anniversary of the grant date."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":136},"source":{"system":"sec-edgar","filing":"0001735276-23-000019","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527623000019/edgardoc.xml","form_type":"4"}},{"id":1990714,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":16563,"kind":"person","name":"SCHULMAN AMY W","position":1,"cik":"0001438226","reported_name":"SCHULMAN AMY W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-02-27T21:13:50.000Z","date":"2023-02-23","kind":"exercise","acquired":true,"shares":136,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":136,"source":{"system":"sec-edgar","filing":"0001735276-23-000019","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527623000019/edgardoc.xml","form_type":"4"}},{"id":2229867,"issuer":{"id":112267,"kind":"organization","name":"SQZ Biotechnologies Co","symbol":"SQZ"},"owners":[{"id":16563,"kind":"person","name":"SCHULMAN AMY W","position":1,"cik":"0001438226","reported_name":"SCHULMAN AMY W","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option","published_at":"2022-06-16T21:01:28.000Z","date":"2022-06-15","kind":"grant","acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests and become exercisable on the earlier of (i) June 15, 2023 or (ii) the day immediately prior to the date of the next annual meeting of stockholders following the date of grant, in each case subject to the recipient's continued service on the Board at such time."}],"balance_after":20000,"derivative":{"exercise_price":3.23,"expiration_date":"2032-06-14","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001209191-22-037493","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1438226/000120919122037493/doc4.xml","form_type":"4"}},{"id":2262173,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":16563,"kind":"person","name":"SCHULMAN AMY W","position":1,"cik":"0001438226","reported_name":"SCHULMAN AMY W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option  (right to buy)","published_at":"2022-05-20T20:06:33.000Z","date":"2022-05-18","kind":"grant","acquired":true,"shares":5153,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This award vests in full upon the earlier of the first anniversary of the grant date and the date of any earlier retirement or resignation of the Reporting Person, provided such date of retirement or resignation occurs no more than 90 days prior to the first anniversary of the grant date."}],"balance_after":5153,"derivative":{"exercise_price":128.31,"exercise_date":"2023-05-18","expiration_date":"2032-05-17","underlying":"Common Stock","underlying_shares":5153},"source":{"system":"sec-edgar","filing":"0001735276-22-000051","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527622000051/edgardoc.xml","form_type":"4"}},{"id":2372508,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":16563,"kind":"person","name":"SCHULMAN AMY W","position":1,"cik":"0001438226","reported_name":"SCHULMAN AMY W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2022-02-25T21:09:03.000Z","date":"2022-02-23","kind":"grant","acquired":true,"shares":136,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of ALNY common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This award vests in full upon the earlier of the first anniversary of the grant date and the date of any earlier retirement or resignation of the Reporting Person, provided such date of retirement or resignation occurs no more than 90 days prior to the first anniversary of the grant date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"This award vests in full upon the earlier of the first anniversary of the grant date and the date of any earlier retirement or resignation of the Reporting Person, provided such date of retirement or resignation occurs no more than 90 days prior to the first anniversary of the grant date."}],"balance_after":136,"derivative":{"underlying":"Common Stock","underlying_shares":136},"source":{"system":"sec-edgar","filing":"0001735276-22-000029","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527622000029/edgardoc.xml","form_type":"4"}},{"id":2459508,"issuer":{"id":112267,"kind":"organization","name":"SQZ Biotechnologies Co","symbol":"SQZ"},"owners":[{"id":16563,"kind":"person","name":"SCHULMAN AMY W","position":1,"cik":"0001438226","reported_name":"SCHULMAN AMY W","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option","published_at":"2021-12-23T22:15:10.000Z","date":"2021-12-22","kind":"exercise","acquired":false,"shares":6581,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Options were exercised and held for tax planning purposes."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F10","text":"The option vests and becomes exercisable in 48 equal monthly installments commencing on July 5, 2019."}],"balance_after":3949,"derivative":{"exercise_price":4.59,"expiration_date":"2029-06-05","underlying":"Common Stock","underlying_shares":6581},"source":{"system":"sec-edgar","filing":"0001209191-21-071110","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1438226/000120919121071110/doc4.xml","form_type":"4"}},{"id":2459507,"issuer":{"id":112267,"kind":"organization","name":"SQZ Biotechnologies Co","symbol":"SQZ"},"owners":[{"id":16563,"kind":"person","name":"SCHULMAN AMY W","position":1,"cik":"0001438226","reported_name":"SCHULMAN AMY W","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option","published_at":"2021-12-23T22:15:10.000Z","date":"2021-12-22","kind":"exercise","acquired":false,"shares":7458,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Options were exercised and held for tax planning purposes."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F9","text":"The option vests and becomes exercisable as to 25% of the underlying securities on February 1, 2020 and in 36 equal monthly installments thereafter."}],"balance_after":3072,"derivative":{"exercise_price":4.59,"expiration_date":"2029-02-18","underlying":"Common Stock","underlying_shares":7458},"source":{"system":"sec-edgar","filing":"0001209191-21-071110","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1438226/000120919121071110/doc4.xml","form_type":"4"}},{"id":2459506,"issuer":{"id":112267,"kind":"organization","name":"SQZ Biotechnologies Co","symbol":"SQZ"},"owners":[{"id":16563,"kind":"person","name":"SCHULMAN AMY W","position":1,"cik":"0001438226","reported_name":"SCHULMAN AMY W","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option","published_at":"2021-12-23T22:15:10.000Z","date":"2021-12-22","kind":"exercise","acquired":false,"shares":10091,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Options were exercised and held for tax planning purposes."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"The option vests and becomes exercisable as to 25% of the underlying securities on January 23, 2019 and in 36 equal monthly installments thereafter."}],"balance_after":439,"derivative":{"exercise_price":2.02,"expiration_date":"2028-03-04","underlying":"Common Stock","underlying_shares":10091},"source":{"system":"sec-edgar","filing":"0001209191-21-071110","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1438226/000120919121071110/doc4.xml","form_type":"4"}},{"id":2459505,"issuer":{"id":112267,"kind":"organization","name":"SQZ Biotechnologies Co","symbol":"SQZ"},"owners":[{"id":16563,"kind":"person","name":"SCHULMAN AMY W","position":1,"cik":"0001438226","reported_name":"SCHULMAN AMY W","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-12-23T22:15:10.000Z","date":"2021-12-22","kind":"exercise","acquired":true,"shares":6581,"price":4.59,"value":30206.79,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Options were exercised and held for tax planning purposes."}],"balance_after":214814,"source":{"system":"sec-edgar","filing":"0001209191-21-071110","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1438226/000120919121071110/doc4.xml","form_type":"4"}},{"id":2459504,"issuer":{"id":112267,"kind":"organization","name":"SQZ Biotechnologies Co","symbol":"SQZ"},"owners":[{"id":16563,"kind":"person","name":"SCHULMAN AMY W","position":1,"cik":"0001438226","reported_name":"SCHULMAN AMY W","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-12-23T22:15:10.000Z","date":"2021-12-22","kind":"exercise","acquired":true,"shares":7458,"price":4.59,"value":34232.22,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Options were exercised and held for tax planning purposes."}],"balance_after":208233,"source":{"system":"sec-edgar","filing":"0001209191-21-071110","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1438226/000120919121071110/doc4.xml","form_type":"4"}},{"id":2459503,"issuer":{"id":112267,"kind":"organization","name":"SQZ Biotechnologies Co","symbol":"SQZ"},"owners":[{"id":16563,"kind":"person","name":"SCHULMAN AMY W","position":1,"cik":"0001438226","reported_name":"SCHULMAN AMY W","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-12-23T22:15:10.000Z","date":"2021-12-22","kind":"exercise","acquired":true,"shares":10091,"price":2.02,"value":20383.82,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Options were exercised and held for tax planning purposes."}],"balance_after":200775,"source":{"system":"sec-edgar","filing":"0001209191-21-071110","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1438226/000120919121071110/doc4.xml","form_type":"4"}},{"id":2471488,"issuer":{"id":112267,"kind":"organization","name":"SQZ Biotechnologies Co","symbol":"SQZ"},"owners":[{"id":16563,"kind":"person","name":"SCHULMAN AMY W","position":1,"cik":"0001438226","reported_name":"SCHULMAN AMY W","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-12-15T22:15:14.000Z","date":"2021-12-13","kind":"purchase","acquired":true,"shares":1850,"price":10.94,"value":20239.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are held in trust 2 for the benefit of a child of the reporting person. The reporting person's spouse has investment authorization over the trust. The reporting person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose."}],"balance_after":1850,"source":{"system":"sec-edgar","filing":"0001209191-21-069790","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1438226/000120919121069790/doc4.xml","form_type":"4"}},{"id":2471487,"issuer":{"id":112267,"kind":"organization","name":"SQZ Biotechnologies Co","symbol":"SQZ"},"owners":[{"id":16563,"kind":"person","name":"SCHULMAN AMY W","position":1,"cik":"0001438226","reported_name":"SCHULMAN AMY W","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-12-15T22:15:14.000Z","date":"2021-12-13","kind":"purchase","acquired":true,"shares":1850,"price":10.88,"value":20128.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"These shares are held in trust 1 for the benefit of a child of the reporting person. The reporting person's spouse has investment authorization over the trust. The reporting person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose."}],"balance_after":1850,"source":{"system":"sec-edgar","filing":"0001209191-21-069790","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1438226/000120919121069790/doc4.xml","form_type":"4"}},{"id":2532037,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":16563,"kind":"person","name":"SCHULMAN AMY W","position":1,"cik":"0001438226","reported_name":"SCHULMAN AMY W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option  (right to buy)","published_at":"2021-10-29T20:07:15.000Z","date":"2021-10-27","kind":"grant","acquired":true,"shares":1814,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This award vests in full upon the earlier of the first anniversary of the grant date and the date of any earlier retirement or resignation of the Reporting Person, provided such date of retirement or resignation occurs no more than 90 days prior to the first anniversary of the grant date."}],"balance_after":1814,"derivative":{"exercise_price":191.16,"exercise_date":"2022-10-27","expiration_date":"2031-10-26","underlying":"Common Stock","underlying_shares":1814},"source":{"system":"sec-edgar","filing":"0001735276-21-000086","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527621000086/edgardoc.xml","form_type":"4"}},{"id":2630795,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":16563,"kind":"person","name":"SCHULMAN AMY W","position":1,"cik":"0001438226","reported_name":"SCHULMAN AMY W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option  (right to buy)","published_at":"2021-07-19T20:21:28.000Z","date":"2021-07-15","kind":"grant","acquired":true,"shares":4032,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This award vests in full upon the earlier of the first anniversary of the grant date and the date of any earlier retirement or resignation of the Reporting Person, provided such date of retirement or resignation occurs no more than 90 days prior to the first anniversary of the grant date."}],"balance_after":4032,"derivative":{"exercise_price":171.95,"exercise_date":"2022-07-15","expiration_date":"2031-07-14","underlying":"Common Stock","underlying_shares":4032},"source":{"system":"sec-edgar","filing":"0001735276-21-000068","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527621000068/edgardoc.xml","form_type":"4"}},{"id":2663495,"issuer":{"id":112267,"kind":"organization","name":"SQZ Biotechnologies Co","symbol":"SQZ"},"owners":[{"id":16563,"kind":"person","name":"SCHULMAN AMY W","position":1,"cik":"0001438226","reported_name":"SCHULMAN AMY W","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option","published_at":"2021-06-17T21:16:15.000Z","date":"2021-06-15","kind":"grant","acquired":true,"shares":10500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests and becomes exercisable on the earlier of (i) June 15, 2022 or (ii) the day immediately prior to the date of the Issuer's next\nannual meeting of stockholders following the date of grant, in each case subject to the Reporting Person's continued service on the Board."}],"balance_after":10500,"derivative":{"exercise_price":13.57,"expiration_date":"2031-06-14","underlying":"Common Stock","underlying_shares":10500},"source":{"system":"sec-edgar","filing":"0001209191-21-041541","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1438226/000120919121041541/doc4.xml","form_type":"4"}},{"id":2749476,"issuer":{"id":130674,"kind":"organization","name":"Hudson Executive Investment Corp. II","symbol":"HCII"},"owners":[{"id":16563,"kind":"person","name":"SCHULMAN AMY W","position":1,"cik":"0001438226","reported_name":"SCHULMAN AMY W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class B Common Stock","published_at":"2021-04-14T20:44:38.000Z","date":"2021-04-13","kind":"purchase","acquired":true,"shares":20000,"price":0.0029,"value":58.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The shares of Class B common stock are convertible for shares of the Issuer's Class A common stock as described under the heading \"Description of Securities\" in the Issuer's Registration Statement on Form S-1 (File No. 333-251848) (the \"Registration Statement\") and have no expiration date"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares of Class B common stock are convertible for shares of the Issuer's Class A common stock as described under the heading \"Description of Securities\" in the Issuer's Registration Statement on Form S-1 (File No. 333-251848) (the \"Registration Statement\") and have no expiration date"},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The shares of Class B common stock are convertible for shares of the Issuer's Class A common stock as described under the heading \"Description of Securities\" in the Issuer's Registration Statement on Form S-1 (File No. 333-251848) (the \"Registration Statement\") and have no expiration date"}],"balance_after":20000,"derivative":{"underlying":"Class A Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0000899243-21-015821","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1438226/000089924321015821/doc4.xml","form_type":"4"}},{"id":2994669,"issuer":{"id":112267,"kind":"organization","name":"SQZ Biotechnologies Co","symbol":"SQZ"},"owners":[{"id":16563,"kind":"person","name":"SCHULMAN AMY W","position":1,"cik":"0001438226","reported_name":"SCHULMAN AMY W","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series D Convertible Preferred Stock","published_at":"2020-11-04T01:00:17.000Z","date":"2020-11-03","kind":"exercise","acquired":false,"shares":93279,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of preferred stock automatically converted on a 1.053 for one basis into common stock upon the closing of the Issuer's initial public offering. The shares have no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of preferred stock automatically converted on a 1.053 for one basis into common stock upon the closing of the Issuer's initial public offering. The shares have no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of preferred stock automatically converted on a 1.053 for one basis into common stock upon the closing of the Issuer's initial public offering. The shares have no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of preferred stock automatically converted on a 1.053 for one basis into common stock upon the closing of the Issuer's initial public offering. The shares have no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"These shares are held of record by LS Polaris Innovation Fund, L.P. (\"LSPIF\"). LS Polaris Innovation Fund GP, L.L.C. (\"LSPIF GP\") is the general partner of LSPIF. The Reporting Person is the sole managing member of LSPIF GP. Each of LSPIF GP and the Reporting Person may be deemed to have sole investment, voting and dispositive power over these shares. LSPIF GP and the Reporting Person disclaim beneficial ownership of the shares held by LSPIF and this report shall not be deemed an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":98222},"source":{"system":"sec-edgar","filing":"0000899243-20-030318","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":17,"url":"https://www.sec.gov/Archives/edgar/data/1438226/000089924320030318/doc4.xml","form_type":"4"}},{"id":2994668,"issuer":{"id":112267,"kind":"organization","name":"SQZ Biotechnologies Co","symbol":"SQZ"},"owners":[{"id":16563,"kind":"person","name":"SCHULMAN AMY W","position":1,"cik":"0001438226","reported_name":"SCHULMAN AMY W","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series D Convertible Preferred Stock","published_at":"2020-11-04T01:00:17.000Z","date":"2020-11-03","kind":"exercise","acquired":false,"shares":348725,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of preferred stock automatically converted on a 1.053 for one basis into common stock upon the closing of the Issuer's initial public offering. The shares have no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of preferred stock automatically converted on a 1.053 for one basis into common stock upon the closing of the Issuer's initial public offering. The shares have no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of preferred stock automatically converted on a 1.053 for one basis into common stock upon the closing of the Issuer's initial public offering. The shares have no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of preferred stock automatically converted on a 1.053 for one basis into common stock upon the closing of the Issuer's initial public offering. The shares have no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Each of the Managing Members and the Reporting Person, in their respective capacities with respect to PMC VII, may be deemed to have shared investment, voting and dispositive power over these shares. Each of PMC VII, the Managing Members and the Reporting Person disclaim beneficial ownership of these shares and this report shall not be deemed an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"These shares are held of record by Polaris Partners VII, L.P. (\"PP VII\"). PMC VII is the general partner of PP VII. The Managing Members are the managing members of PMC VII. The Reporting Person, a member of the Issuer's board of directors, holds an interest in PMC VII."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":367207},"source":{"system":"sec-edgar","filing":"0000899243-20-030318","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":16,"url":"https://www.sec.gov/Archives/edgar/data/1438226/000089924320030318/doc4.xml","form_type":"4"}},{"id":2994667,"issuer":{"id":112267,"kind":"organization","name":"SQZ Biotechnologies Co","symbol":"SQZ"},"owners":[{"id":16563,"kind":"person","name":"SCHULMAN AMY W","position":1,"cik":"0001438226","reported_name":"SCHULMAN AMY W","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series D Convertible Preferred Stock","published_at":"2020-11-04T01:00:17.000Z","date":"2020-11-03","kind":"exercise","acquired":false,"shares":24396,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of preferred stock automatically converted on a 1.053 for one basis into common stock upon the closing of the Issuer's initial public offering. The shares have no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of preferred stock automatically converted on a 1.053 for one basis into common stock upon the closing of the Issuer's initial public offering. The shares have no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of preferred stock automatically converted on a 1.053 for one basis into common stock upon the closing of the Issuer's initial public offering. The shares have no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of preferred stock automatically converted on a 1.053 for one basis into common stock upon the closing of the Issuer's initial public offering. The shares have no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are held of record by Polaris Entrepreneurs' Fund VII, L.P. (\"EF VII\"). Polaris Management Co. VII, L.L.C. (\"PMC VII\") is the general partner of EF VII. David Barrett, Brian Chee, Amir Nashat and Bryce Youngren (the \"Managing Members\") are the managing members of PMC VII. The Reporting Person, a member of the Issuer's board of directors, holds an interest in PMC VII."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Each of the Managing Members and the Reporting Person, in their respective capacities with respect to PMC VII, may be deemed to have shared investment, voting and dispositive power over these shares. Each of PMC VII, the Managing Members and the Reporting Person disclaim beneficial ownership of these shares and this report shall not be deemed an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":25690},"source":{"system":"sec-edgar","filing":"0000899243-20-030318","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":15,"url":"https://www.sec.gov/Archives/edgar/data/1438226/000089924320030318/doc4.xml","form_type":"4"}},{"id":2994666,"issuer":{"id":112267,"kind":"organization","name":"SQZ Biotechnologies Co","symbol":"SQZ"},"owners":[{"id":16563,"kind":"person","name":"SCHULMAN AMY W","position":1,"cik":"0001438226","reported_name":"SCHULMAN AMY W","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series C Convertible Preferred Stock","published_at":"2020-11-04T01:00:17.000Z","date":"2020-11-03","kind":"exercise","acquired":false,"shares":21087,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of preferred stock automatically converted on a 1.053 for one basis into common stock upon the closing of the Issuer's initial public offering. The shares have no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of preferred stock automatically converted on a 1.053 for one basis into common stock upon the closing of the Issuer's initial public offering. The shares have no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of preferred stock automatically converted on a 1.053 for one basis into common stock upon the closing of the Issuer's initial public offering. The shares have no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of preferred stock automatically converted on a 1.053 for one basis into common stock upon the closing of the Issuer's initial public offering. The shares have no expiration date."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":22204},"source":{"system":"sec-edgar","filing":"0000899243-20-030318","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":14,"url":"https://www.sec.gov/Archives/edgar/data/1438226/000089924320030318/doc4.xml","form_type":"4"}},{"id":2994665,"issuer":{"id":112267,"kind":"organization","name":"SQZ Biotechnologies Co","symbol":"SQZ"},"owners":[{"id":16563,"kind":"person","name":"SCHULMAN AMY W","position":1,"cik":"0001438226","reported_name":"SCHULMAN AMY W","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series C Convertible Preferred Stock","published_at":"2020-11-04T01:00:17.000Z","date":"2020-11-03","kind":"exercise","acquired":false,"shares":168698,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of preferred stock automatically converted on a 1.053 for one basis into common stock upon the closing of the Issuer's initial public offering. The shares have no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of preferred stock automatically converted on a 1.053 for one basis into common stock upon the closing of the Issuer's initial public offering. The shares have no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of preferred stock automatically converted on a 1.053 for one basis into common stock upon the closing of the Issuer's initial public offering. The shares have no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of preferred stock automatically converted on a 1.053 for one basis into common stock upon the closing of the Issuer's initial public offering. The shares have no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"These shares are held of record by LS Polaris Innovation Fund, L.P. (\"LSPIF\"). LS Polaris Innovation Fund GP, L.L.C. (\"LSPIF GP\") is the general partner of LSPIF. The Reporting Person is the sole managing member of LSPIF GP. Each of LSPIF GP and the Reporting Person may be deemed to have sole investment, voting and dispositive power over these shares. LSPIF GP and the Reporting Person disclaim beneficial ownership of the shares held by LSPIF and this report shall not be deemed an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":177638},"source":{"system":"sec-edgar","filing":"0000899243-20-030318","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1438226/000089924320030318/doc4.xml","form_type":"4"}},{"id":2994664,"issuer":{"id":112267,"kind":"organization","name":"SQZ Biotechnologies Co","symbol":"SQZ"},"owners":[{"id":16563,"kind":"person","name":"SCHULMAN AMY W","position":1,"cik":"0001438226","reported_name":"SCHULMAN AMY W","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series C Convertible Preferred Stock","published_at":"2020-11-04T01:00:17.000Z","date":"2020-11-03","kind":"exercise","acquired":false,"shares":630672,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of preferred stock automatically converted on a 1.053 for one basis into common stock upon the closing of the Issuer's initial public offering. The shares have no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of preferred stock automatically converted on a 1.053 for one basis into common stock upon the closing of the Issuer's initial public offering. The shares have no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of preferred stock automatically converted on a 1.053 for one basis into common stock upon the closing of the Issuer's initial public offering. The shares have no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of preferred stock automatically converted on a 1.053 for one basis into common stock upon the closing of the Issuer's initial public offering. The shares have no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Each of the Managing Members and the Reporting Person, in their respective capacities with respect to PMC VII, may be deemed to have shared investment, voting and dispositive power over these shares. Each of PMC VII, the Managing Members and the Reporting Person disclaim beneficial ownership of these shares and this report shall not be deemed an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"These shares are held of record by Polaris Partners VII, L.P. (\"PP VII\"). PMC VII is the general partner of PP VII. The Managing Members are the managing members of PMC VII. The Reporting Person, a member of the Issuer's board of directors, holds an interest in PMC VII."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":664097},"source":{"system":"sec-edgar","filing":"0000899243-20-030318","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1438226/000089924320030318/doc4.xml","form_type":"4"}},{"id":2994663,"issuer":{"id":112267,"kind":"organization","name":"SQZ Biotechnologies Co","symbol":"SQZ"},"owners":[{"id":16563,"kind":"person","name":"SCHULMAN AMY W","position":1,"cik":"0001438226","reported_name":"SCHULMAN AMY W","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series C Convertible Preferred Stock","published_at":"2020-11-04T01:00:17.000Z","date":"2020-11-03","kind":"exercise","acquired":false,"shares":44120,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of preferred stock automatically converted on a 1.053 for one basis into common stock upon the closing of the Issuer's initial public offering. The shares have no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of preferred stock automatically converted on a 1.053 for one basis into common stock upon the closing of the Issuer's initial public offering. The shares have no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of preferred stock automatically converted on a 1.053 for one basis into common stock upon the closing of the Issuer's initial public offering. The shares have no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of preferred stock automatically converted on a 1.053 for one basis into common stock upon the closing of the Issuer's initial public offering. The shares have no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are held of record by Polaris Entrepreneurs' Fund VII, L.P. (\"EF VII\"). Polaris Management Co. VII, L.L.C. (\"PMC VII\") is the general partner of EF VII. David Barrett, Brian Chee, Amir Nashat and Bryce Youngren (the \"Managing Members\") are the managing members of PMC VII. The Reporting Person, a member of the Issuer's board of directors, holds an interest in PMC VII."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Each of the Managing Members and the Reporting Person, in their respective capacities with respect to PMC VII, may be deemed to have shared investment, voting and dispositive power over these shares. Each of PMC VII, the Managing Members and the Reporting Person disclaim beneficial ownership of these shares and this report shall not be deemed an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":46458},"source":{"system":"sec-edgar","filing":"0000899243-20-030318","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1438226/000089924320030318/doc4.xml","form_type":"4"}},{"id":2994662,"issuer":{"id":112267,"kind":"organization","name":"SQZ Biotechnologies Co","symbol":"SQZ"},"owners":[{"id":16563,"kind":"person","name":"SCHULMAN AMY W","position":1,"cik":"0001438226","reported_name":"SCHULMAN AMY W","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Convertible Preferred Stock","published_at":"2020-11-04T01:00:17.000Z","date":"2020-11-03","kind":"exercise","acquired":false,"shares":807096,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of preferred stock automatically converted on a 1.053 for one basis into common stock upon the closing of the Issuer's initial public offering. The shares have no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of preferred stock automatically converted on a 1.053 for one basis into common stock upon the closing of the Issuer's initial public offering. The shares have no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of preferred stock automatically converted on a 1.053 for one basis into common stock upon the closing of the Issuer's initial public offering. The shares have no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of preferred stock automatically converted on a 1.053 for one basis into common stock upon the closing of the Issuer's initial public offering. The shares have no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Each of the Managing Members and the Reporting Person, in their respective capacities with respect to PMC VII, may be deemed to have shared investment, voting and dispositive power over these shares. Each of PMC VII, the Managing Members and the Reporting Person disclaim beneficial ownership of these shares and this report shall not be deemed an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"These shares are held of record by Polaris Partners VII, L.P. (\"PP VII\"). PMC VII is the general partner of PP VII. The Managing Members are the managing members of PMC VII. The Reporting Person, a member of the Issuer's board of directors, holds an interest in PMC VII."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":849872},"source":{"system":"sec-edgar","filing":"0000899243-20-030318","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1438226/000089924320030318/doc4.xml","form_type":"4"}},{"id":2994661,"issuer":{"id":112267,"kind":"organization","name":"SQZ Biotechnologies Co","symbol":"SQZ"},"owners":[{"id":16563,"kind":"person","name":"SCHULMAN AMY W","position":1,"cik":"0001438226","reported_name":"SCHULMAN AMY W","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Convertible Preferred Stock","published_at":"2020-11-04T01:00:17.000Z","date":"2020-11-03","kind":"exercise","acquired":false,"shares":56462,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of preferred stock automatically converted on a 1.053 for one basis into common stock upon the closing of the Issuer's initial public offering. The shares have no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of preferred stock automatically converted on a 1.053 for one basis into common stock upon the closing of the Issuer's initial public offering. The shares have no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of preferred stock automatically converted on a 1.053 for one basis into common stock upon the closing of the Issuer's initial public offering. The shares have no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of preferred stock automatically converted on a 1.053 for one basis into common stock upon the closing of the Issuer's initial public offering. The shares have no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are held of record by Polaris Entrepreneurs' Fund VII, L.P. (\"EF VII\"). Polaris Management Co. VII, L.L.C. (\"PMC VII\") is the general partner of EF VII. David Barrett, Brian Chee, Amir Nashat and Bryce Youngren (the \"Managing Members\") are the managing members of PMC VII. The Reporting Person, a member of the Issuer's board of directors, holds an interest in PMC VII."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Each of the Managing Members and the Reporting Person, in their respective capacities with respect to PMC VII, may be deemed to have shared investment, voting and dispositive power over these shares. Each of PMC VII, the Managing Members and the Reporting Person disclaim beneficial ownership of these shares and this report shall not be deemed an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":59454},"source":{"system":"sec-edgar","filing":"0000899243-20-030318","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1438226/000089924320030318/doc4.xml","form_type":"4"}},{"id":2994660,"issuer":{"id":112267,"kind":"organization","name":"SQZ Biotechnologies Co","symbol":"SQZ"},"owners":[{"id":16563,"kind":"person","name":"SCHULMAN AMY W","position":1,"cik":"0001438226","reported_name":"SCHULMAN AMY W","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Convertible Preferred Stock","published_at":"2020-11-04T01:00:17.000Z","date":"2020-11-03","kind":"exercise","acquired":false,"shares":412608,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of preferred stock automatically converted on a 1.053 for one basis into common stock upon the closing of the Issuer's initial public offering. The shares have no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of preferred stock automatically converted on a 1.053 for one basis into common stock upon the closing of the Issuer's initial public offering. The shares have no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of preferred stock automatically converted on a 1.053 for one basis into common stock upon the closing of the Issuer's initial public offering. The shares have no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of preferred stock automatically converted on a 1.053 for one basis into common stock upon the closing of the Issuer's initial public offering. The shares have no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Each of the Managing Members and the Reporting Person, in their respective capacities with respect to PMC VII, may be deemed to have shared investment, voting and dispositive power over these shares. Each of PMC VII, the Managing Members and the Reporting Person disclaim beneficial ownership of these shares and this report shall not be deemed an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"These shares are held of record by Polaris Partners VII, L.P. (\"PP VII\"). PMC VII is the general partner of PP VII. The Managing Members are the managing members of PMC VII. The Reporting Person, a member of the Issuer's board of directors, holds an interest in PMC VII."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":434476},"source":{"system":"sec-edgar","filing":"0000899243-20-030318","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1438226/000089924320030318/doc4.xml","form_type":"4"}},{"id":2994659,"issuer":{"id":112267,"kind":"organization","name":"SQZ Biotechnologies Co","symbol":"SQZ"},"owners":[{"id":16563,"kind":"person","name":"SCHULMAN AMY W","position":1,"cik":"0001438226","reported_name":"SCHULMAN AMY W","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Convertible Preferred Stock","published_at":"2020-11-04T01:00:17.000Z","date":"2020-11-03","kind":"exercise","acquired":false,"shares":28863,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of preferred stock automatically converted on a 1.053 for one basis into common stock upon the closing of the Issuer's initial public offering. The shares have no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of preferred stock automatically converted on a 1.053 for one basis into common stock upon the closing of the Issuer's initial public offering. The shares have no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of preferred stock automatically converted on a 1.053 for one basis into common stock upon the closing of the Issuer's initial public offering. The shares have no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of preferred stock automatically converted on a 1.053 for one basis into common stock upon the closing of the Issuer's initial public offering. The shares have no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are held of record by Polaris Entrepreneurs' Fund VII, L.P. (\"EF VII\"). Polaris Management Co. VII, L.L.C. (\"PMC VII\") is the general partner of EF VII. David Barrett, Brian Chee, Amir Nashat and Bryce Youngren (the \"Managing Members\") are the managing members of PMC VII. The Reporting Person, a member of the Issuer's board of directors, holds an interest in PMC VII."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Each of the Managing Members and the Reporting Person, in their respective capacities with respect to PMC VII, may be deemed to have shared investment, voting and dispositive power over these shares. Each of PMC VII, the Managing Members and the Reporting Person disclaim beneficial ownership of these shares and this report shall not be deemed an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":30392},"source":{"system":"sec-edgar","filing":"0000899243-20-030318","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1438226/000089924320030318/doc4.xml","form_type":"4"}},{"id":2994658,"issuer":{"id":112267,"kind":"organization","name":"SQZ Biotechnologies Co","symbol":"SQZ"},"owners":[{"id":16563,"kind":"person","name":"SCHULMAN AMY W","position":1,"cik":"0001438226","reported_name":"SCHULMAN AMY W","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-11-04T01:00:17.000Z","date":"2020-11-03","kind":"purchase","acquired":true,"shares":233654,"price":16,"value":3738464.0,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Each of the Managing Members and the Reporting Person, in their respective capacities with respect to PMC VII, may be deemed to have shared investment, voting and dispositive power over these shares. Each of PMC VII, the Managing Members and the Reporting Person disclaim beneficial ownership of these shares and this report shall not be deemed an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"These shares are held of record by Polaris Partners VII, L.P. (\"PP VII\"). PMC VII is the general partner of PP VII. The Managing Members are the managing members of PMC VII. The Reporting Person, a member of the Issuer's board of directors, holds an interest in PMC VII."}],"balance_after":2549306,"source":{"system":"sec-edgar","filing":"0000899243-20-030318","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1438226/000089924320030318/doc4.xml","form_type":"4"}},{"id":2994657,"issuer":{"id":112267,"kind":"organization","name":"SQZ Biotechnologies Co","symbol":"SQZ"},"owners":[{"id":16563,"kind":"person","name":"SCHULMAN AMY W","position":1,"cik":"0001438226","reported_name":"SCHULMAN AMY W","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-11-04T01:00:17.000Z","date":"2020-11-03","kind":"purchase","acquired":true,"shares":16346,"price":16,"value":261536.0,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are held of record by Polaris Entrepreneurs' Fund VII, L.P. (\"EF VII\"). Polaris Management Co. VII, L.L.C. (\"PMC VII\") is the general partner of EF VII. David Barrett, Brian Chee, Amir Nashat and Bryce Youngren (the \"Managing Members\") are the managing members of PMC VII. The Reporting Person, a member of the Issuer's board of directors, holds an interest in PMC VII."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Each of the Managing Members and the Reporting Person, in their respective capacities with respect to PMC VII, may be deemed to have shared investment, voting and dispositive power over these shares. Each of PMC VII, the Managing Members and the Reporting Person disclaim beneficial ownership of these shares and this report shall not be deemed an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein."}],"balance_after":178340,"source":{"system":"sec-edgar","filing":"0000899243-20-030318","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1438226/000089924320030318/doc4.xml","form_type":"4"}},{"id":2994656,"issuer":{"id":112267,"kind":"organization","name":"SQZ Biotechnologies Co","symbol":"SQZ"},"owners":[{"id":16563,"kind":"person","name":"SCHULMAN AMY W","position":1,"cik":"0001438226","reported_name":"SCHULMAN AMY W","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-11-04T01:00:17.000Z","date":"2020-11-03","kind":"exercise","acquired":true,"shares":275860,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of preferred stock automatically converted on a 1.053 for one basis into common stock upon the closing of the Issuer's initial public offering. The shares have no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"These shares are held of record by LS Polaris Innovation Fund, L.P. (\"LSPIF\"). LS Polaris Innovation Fund GP, L.L.C. (\"LSPIF GP\") is the general partner of LSPIF. The Reporting Person is the sole managing member of LSPIF GP. Each of LSPIF GP and the Reporting Person may be deemed to have sole investment, voting and dispositive power over these shares. LSPIF GP and the Reporting Person disclaim beneficial ownership of the shares held by LSPIF and this report shall not be deemed an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein."}],"balance_after":275860,"source":{"system":"sec-edgar","filing":"0000899243-20-030318","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1438226/000089924320030318/doc4.xml","form_type":"4"}},{"id":2994655,"issuer":{"id":112267,"kind":"organization","name":"SQZ Biotechnologies Co","symbol":"SQZ"},"owners":[{"id":16563,"kind":"person","name":"SCHULMAN AMY W","position":1,"cik":"0001438226","reported_name":"SCHULMAN AMY W","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-11-04T01:00:17.000Z","date":"2020-11-03","kind":"exercise","acquired":true,"shares":2315652,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of preferred stock automatically converted on a 1.053 for one basis into common stock upon the closing of the Issuer's initial public offering. The shares have no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Each of the Managing Members and the Reporting Person, in their respective capacities with respect to PMC VII, may be deemed to have shared investment, voting and dispositive power over these shares. Each of PMC VII, the Managing Members and the Reporting Person disclaim beneficial ownership of these shares and this report shall not be deemed an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"These shares are held of record by Polaris Partners VII, L.P. (\"PP VII\"). PMC VII is the general partner of PP VII. The Managing Members are the managing members of PMC VII. The Reporting Person, a member of the Issuer's board of directors, holds an interest in PMC VII."}],"balance_after":2315652,"source":{"system":"sec-edgar","filing":"0000899243-20-030318","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1438226/000089924320030318/doc4.xml","form_type":"4"}},{"id":2994654,"issuer":{"id":112267,"kind":"organization","name":"SQZ Biotechnologies Co","symbol":"SQZ"},"owners":[{"id":16563,"kind":"person","name":"SCHULMAN AMY W","position":1,"cik":"0001438226","reported_name":"SCHULMAN AMY W","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-11-04T01:00:17.000Z","date":"2020-11-03","kind":"exercise","acquired":true,"shares":161994,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of preferred stock automatically converted on a 1.053 for one basis into common stock upon the closing of the Issuer's initial public offering. The shares have no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are held of record by Polaris Entrepreneurs' Fund VII, L.P. (\"EF VII\"). Polaris Management Co. VII, L.L.C. (\"PMC VII\") is the general partner of EF VII. David Barrett, Brian Chee, Amir Nashat and Bryce Youngren (the \"Managing Members\") are the managing members of PMC VII. The Reporting Person, a member of the Issuer's board of directors, holds an interest in PMC VII."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Each of the Managing Members and the Reporting Person, in their respective capacities with respect to PMC VII, may be deemed to have shared investment, voting and dispositive power over these shares. Each of PMC VII, the Managing Members and the Reporting Person disclaim beneficial ownership of these shares and this report shall not be deemed an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein."}],"balance_after":161994,"source":{"system":"sec-edgar","filing":"0000899243-20-030318","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1438226/000089924320030318/doc4.xml","form_type":"4"}},{"id":2994653,"issuer":{"id":112267,"kind":"organization","name":"SQZ Biotechnologies Co","symbol":"SQZ"},"owners":[{"id":16563,"kind":"person","name":"SCHULMAN AMY W","position":1,"cik":"0001438226","reported_name":"SCHULMAN AMY W","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-11-04T01:00:17.000Z","date":"2020-11-03","kind":"exercise","acquired":true,"shares":22204,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of preferred stock automatically converted on a 1.053 for one basis into common stock upon the closing of the Issuer's initial public offering. The shares have no expiration date."}],"balance_after":190684,"source":{"system":"sec-edgar","filing":"0000899243-20-030318","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1438226/000089924320030318/doc4.xml","form_type":"4"}},{"id":2997409,"issuer":{"id":112267,"kind":"organization","name":"SQZ Biotechnologies Co","symbol":"SQZ"},"owners":[{"id":16563,"kind":"person","name":"SCHULMAN AMY W","position":1,"cik":"0001438226","reported_name":"SCHULMAN AMY W","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option","published_at":"2020-10-30T22:30:14.000Z","date":"2020-10-29","kind":"grant","acquired":true,"shares":7055,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests and becomes exercisable on October 29, 2021."}],"balance_after":7055,"derivative":{"exercise_price":16,"expiration_date":"2030-10-28","underlying":"Common Stock","underlying_shares":7055},"source":{"system":"sec-edgar","filing":"0000899243-20-029974","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1438226/000089924320029974/doc4.xml","form_type":"4"}},{"id":3089165,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":16563,"kind":"person","name":"SCHULMAN AMY W","position":1,"cik":"0001438226","reported_name":"SCHULMAN AMY W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option  (right to buy)","published_at":"2020-07-06T20:50:56.000Z","date":"2020-07-01","kind":"grant","acquired":true,"shares":4581,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":4581,"derivative":{"exercise_price":148.77,"exercise_date":"2021-07-01","expiration_date":"2030-07-01","underlying":"Common Stock","underlying_shares":4581},"source":{"system":"sec-edgar","filing":"0001735276-20-000076","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527620000076/edgardoc.xml","form_type":"4"}},{"id":3105381,"issuer":{"id":7698,"kind":"organization","name":"Korsana Biosciences, Inc.","symbol":"KRSA"},"owners":[{"id":16563,"kind":"person","name":"SCHULMAN AMY W","position":1,"cik":"0001438226","reported_name":"SCHULMAN AMY W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-06-18T20:15:40.000Z","date":"2020-06-16","kind":"grant","acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options, granted pursuant to the director compensation plan, will vest in full on the first anniversary of the grant date."}],"balance_after":10000,"derivative":{"exercise_price":4.46,"expiration_date":"2030-06-16","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001209191-20-037566","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1438226/000120919120037566/doc4.xml","form_type":"4"}},{"id":3471570,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":16563,"kind":"person","name":"SCHULMAN AMY W","position":1,"cik":"0001438226","reported_name":"SCHULMAN AMY W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option  (right to buy)","published_at":"2019-07-02T20:07:11.000Z","date":"2019-07-01","kind":"grant","acquired":true,"shares":9000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":9000,"derivative":{"exercise_price":72.01,"exercise_date":"2020-07-01","expiration_date":"2029-06-30","underlying":"Common Stock","underlying_shares":9000},"source":{"system":"sec-edgar","filing":"0001735276-19-000066","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527619000066/edgardoc.xml","form_type":"4"}},{"id":3502262,"issuer":{"id":7698,"kind":"organization","name":"Korsana Biosciences, Inc.","symbol":"KRSA"},"owners":[{"id":16563,"kind":"person","name":"SCHULMAN AMY W","position":1,"cik":"0001438226","reported_name":"SCHULMAN AMY W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2019-06-04T20:59:00.000Z","date":"2019-06-01","kind":"grant","acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options, granted pursuant to the director compensation plan, will vest in full on the first anniversary of the grant date."}],"balance_after":10000,"derivative":{"exercise_price":13.95,"expiration_date":"2029-06-01","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001209191-19-034383","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1438226/000120919119034383/doc4.xml","form_type":"4"}},{"id":3558386,"issuer":{"id":7698,"kind":"organization","name":"Korsana Biosciences, Inc.","symbol":"KRSA"},"owners":[{"id":16563,"kind":"person","name":"SCHULMAN AMY W","position":1,"cik":"0001438226","reported_name":"SCHULMAN AMY W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-04-10T20:13:54.000Z","date":"2019-04-08","kind":"purchase","acquired":true,"shares":21635,"price":16,"value":346160.0,"ownership":{"direct":false,"nature":"By Polaris Entrepreneurs' Fund VIII, L.P."},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares were acquired from unaffiliated stockholders in a negotiated, private transaction."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The reportable securities are owned directly by Polaris Entrepreneurs' Fund VIII, L.P. (\"PEF VIII\"). PPGP VIII is the general partner of PEF VIII. The Reporting Person, a member of the Issuer's Board of Directors, is an interest holder of PPGP VIII. Each of the Reporting Person and the Managing Members, in their respective capacities with respect to PPGP VIII, may be deemed to have shared voting and dispositive power over the shares held by PEF VIII. Each of PPGP VIII, the Reporting Person and the Managing Members disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein."}],"balance_after":21635,"source":{"system":"sec-edgar","filing":"0001209191-19-024236","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1438226/000120919119024236/doc4.xml","form_type":"4"}},{"id":3558385,"issuer":{"id":7698,"kind":"organization","name":"Korsana Biosciences, Inc.","symbol":"KRSA"},"owners":[{"id":16563,"kind":"person","name":"SCHULMAN AMY W","position":1,"cik":"0001438226","reported_name":"SCHULMAN AMY W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-04-10T20:13:54.000Z","date":"2019-04-08","kind":"purchase","acquired":true,"shares":604482,"price":16,"value":9671712.0,"ownership":{"direct":false,"nature":"By Polaris Partners VIII, L.P."},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares were acquired from unaffiliated stockholders in a negotiated, private transaction."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The reportable securities are owned directly by Polaris Partners VIII, L.P. (\"PP VIII\"). Polaris Partners GP VIII, L.L.C. (\"PPGP VIII\") is the general partner of PP VIII. The Reporting Person, a member of the Issuer's Board of Directors, is an interest holder of PPGP VIII. Each of David Barrett, Brian Chee, Amir Nashat and Bryce Youngren are the managing members of PPGP VIII (collectively, the \"Managing Members\"). Each of the Reporting Person and the Managing Members, in their respective capacities with respect to PPGP VIII, may be deemed to have shared voting and dispositive power over the shares held by PP VIII. Each of PPGP VIII, the Reporting Person and the Managing Members disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein."}],"balance_after":604482,"source":{"system":"sec-edgar","filing":"0001209191-19-024236","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1438226/000120919119024236/doc4.xml","form_type":"4"}},{"id":3564655,"issuer":{"id":7698,"kind":"organization","name":"Korsana Biosciences, Inc.","symbol":"KRSA"},"owners":[{"id":16563,"kind":"person","name":"SCHULMAN AMY W","position":1,"cik":"0001438226","reported_name":"SCHULMAN AMY W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-04-03T23:34:32.000Z","date":"2019-04-01","kind":"grant","acquired":true,"shares":3279,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents shares of Cyclerion common stock granted to the reporting person as a result of adjustments to existing Ironwood shares of common stock made in connection with the Separation."}],"balance_after":7508,"source":{"system":"sec-edgar","filing":"0001209191-19-023514","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1438226/000120919119023514/doc4.xml","form_type":"4"}},{"id":3564654,"issuer":{"id":7698,"kind":"organization","name":"Korsana Biosciences, Inc.","symbol":"KRSA"},"owners":[{"id":16563,"kind":"person","name":"SCHULMAN AMY W","position":1,"cik":"0001438226","reported_name":"SCHULMAN AMY W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-04-03T23:34:32.000Z","date":"2019-04-01","kind":"grant","acquired":true,"shares":4229,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"In connection with the separation (the \"Separation\") of Cyclerion Therapeutics, Inc. (\"Cyclerion\") from Ironwood Pharmaceuticals, Inc. (\"Ironwood\"), the reporting person received Cyclerion shares representing an equitable adjustment of Ironwood shares held by the reporting person prior to the Separation."}],"balance_after":4229,"source":{"system":"sec-edgar","filing":"0001209191-19-023514","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1438226/000120919119023514/doc4.xml","form_type":"4"}},{"id":3564582,"issuer":{"id":5213,"kind":"organization","name":"IRONWOOD PHARMACEUTICALS INC","symbol":"IRWD"},"owners":[{"id":16563,"kind":"person","name":"SCHULMAN AMY W","position":1,"cik":"0001438226","reported_name":"SCHULMAN AMY W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A Common Stock","published_at":"2019-04-03T22:05:44.000Z","date":"2019-04-01","kind":"disposition_to_issuer","acquired":false,"shares":4056,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents the disposition of 4,056 shares of restricted stock in connection with the separation of Cyclerion Therapeutics, Inc. (\"Cyclerion\") from Ironwood Pharmaceuticals, Inc. in exchange for restricted shares of Cyclerion Common Stock."}],"balance_after":38242,"source":{"system":"sec-edgar","filing":"0001209191-19-023419","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1446847/000120919119023419/doc4.xml","form_type":"4"}},{"id":3586464,"issuer":{"id":5213,"kind":"organization","name":"IRONWOOD PHARMACEUTICALS INC","symbol":"IRWD"},"owners":[{"id":16563,"kind":"person","name":"SCHULMAN AMY W","position":1,"cik":"0001438226","reported_name":"SCHULMAN AMY W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A Common Stock","published_at":"2019-03-19T20:06:11.000Z","date":"2019-03-15","kind":"grant","acquired":true,"shares":183,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Issued pursuant to the Director Compensation Plan, effective as of January 2014."}],"balance_after":42298,"source":{"system":"sec-edgar","filing":"0001209191-19-020265","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1446847/000120919119020265/doc4.xml","form_type":"4"}},{"id":3726711,"issuer":{"id":5213,"kind":"organization","name":"IRONWOOD PHARMACEUTICALS INC","symbol":"IRWD"},"owners":[{"id":16563,"kind":"person","name":"SCHULMAN AMY W","position":1,"cik":"0001438226","reported_name":"SCHULMAN AMY W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A Common Stock","published_at":"2018-12-18T22:28:40.000Z","date":"2018-12-14","kind":"grant","acquired":true,"shares":212,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Issued pursuant to the Director Compensation Plan, effective as of January 2014."}],"balance_after":42115,"source":{"system":"sec-edgar","filing":"0001209191-18-063261","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1446847/000120919118063261/doc4.xml","form_type":"4"}},{"id":3812632,"issuer":{"id":5213,"kind":"organization","name":"IRONWOOD PHARMACEUTICALS INC","symbol":"IRWD"},"owners":[{"id":16563,"kind":"person","name":"SCHULMAN AMY W","position":1,"cik":"0001438226","reported_name":"SCHULMAN AMY W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A Common Stock","published_at":"2018-09-18T20:21:36.000Z","date":"2018-09-14","kind":"grant","acquired":true,"shares":136,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Issued pursuant to the Director Compensation Plan, effective as of January 2014."}],"balance_after":41903,"source":{"system":"sec-edgar","filing":"0001209191-18-051466","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1446847/000120919118051466/doc4.xml","form_type":"4"}},{"id":3885267,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":16563,"kind":"person","name":"SCHULMAN AMY W","position":1,"cik":"0001438226","reported_name":"SCHULMAN AMY W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option  (right to buy)","published_at":"2018-06-22T20:19:59.000Z","date":"2018-06-20","kind":"grant","acquired":true,"shares":9000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":9000,"derivative":{"exercise_price":105.26,"exercise_date":"2019-06-20","expiration_date":"2028-06-19","underlying":"Common Stock","underlying_shares":9000},"source":{"system":"sec-edgar","filing":"0001735276-18-000033","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527618000033/edgardoc.xml","form_type":"4"}},{"id":3888524,"issuer":{"id":5213,"kind":"organization","name":"IRONWOOD PHARMACEUTICALS INC","symbol":"IRWD"},"owners":[{"id":16563,"kind":"person","name":"SCHULMAN AMY W","position":1,"cik":"0001438226","reported_name":"SCHULMAN AMY W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A Common Stock","published_at":"2018-06-19T22:43:23.000Z","date":"2018-06-15","kind":"grant","acquired":true,"shares":126,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Issued pursuant to the Director Compensation Plan, effective as of January 2014."}],"balance_after":41767,"source":{"system":"sec-edgar","filing":"0001209191-18-038676","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1446847/000120919118038676/doc4.xml","form_type":"4"}},{"id":3901529,"issuer":{"id":5638,"kind":"organization","name":"X4 Pharmaceuticals, Inc","symbol":"XFOR"},"owners":[{"id":16563,"kind":"person","name":"SCHULMAN AMY W","position":1,"cik":"0001438226","reported_name":"SCHULMAN AMY W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2018-06-07T20:24:54.000Z","date":"2018-06-05","kind":"grant","acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option becomes exercisable as to 1/12th of the shares underlying the award on the one-month anniversary of the date of grant, with the remainder vesting in equal monthly installments until the first anniversary of the date of grant, subject to the Reporting Person's continued service as a director through each applicable vesting date."}],"balance_after":10000,"derivative":{"exercise_price":16.99,"expiration_date":"2028-06-04","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001209191-18-036350","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1438226/000120919118036350/doc4.xml","form_type":"4"}},{"id":3908259,"issuer":{"id":5213,"kind":"organization","name":"IRONWOOD PHARMACEUTICALS INC","symbol":"IRWD"},"owners":[{"id":16563,"kind":"person","name":"SCHULMAN AMY W","position":1,"cik":"0001438226","reported_name":"SCHULMAN AMY W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A Common Stock","published_at":"2018-06-04T21:30:48.000Z","date":"2018-05-31","kind":"grant","acquired":true,"shares":16223,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Issued pursuant to the Director Compensation Plan, effective as of January 2014."}],"balance_after":41641,"source":{"system":"sec-edgar","filing":"0001209191-18-035251","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1446847/000120919118035251/doc4.xml","form_type":"4"}},{"id":3957989,"issuer":{"id":167336,"kind":"organization","name":"Blue Buffalo Pet Products, Inc.","symbol":"BUFF"},"owners":[{"id":16563,"kind":"person","name":"SCHULMAN AMY W","position":1,"cik":"0001438226","reported_name":"SCHULMAN AMY W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-04-24T20:52:16.000Z","date":"2018-04-24","kind":"disposition_to_issuer","acquired":false,"shares":14819,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On April 24, 2018, General Mills, Inc., a Delaware corporation (\"Buyer\"), acquired the Issuer pursuant to that certain Agreement and Plan of Merger entered into by and among the Issuer, Buyer and Bravo Merger Corp., a Delaware corporation and wholly-owned subsidiary of Buyer (\"Merger Sub\"), dated as of February 22, 2018 (the \"Merger Agreement\"). In accordance with the Merger Agreement, Merger Sub merged with and into the Issuer, with the Issuer surviving such merger as a wholly-owned subsidiary of Buyer (the \"Merger\")."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"At the effective time of the Merger, each outstanding share of the Issuer's common stock (other than certain excluded shares) automatically converted into the right to receive $40.00 in cash, without interest and after giving effect to any required withholding taxes."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000899243-18-010663","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1438226/000089924318010663/doc4.xml","form_type":"4"}},{"id":4014815,"issuer":{"id":5638,"kind":"organization","name":"X4 Pharmaceuticals, Inc","symbol":"XFOR"},"owners":[{"id":16563,"kind":"person","name":"SCHULMAN AMY W","position":1,"cik":"0001438226","reported_name":"SCHULMAN AMY W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock (right to buy)","published_at":"2018-03-05T22:03:14.000Z","date":"2017-11-15","kind":"grant","acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Consists of an automatic stock option grant that was made pursuant to the issuer's director compensation policy on November 15, 2017, the date of effectiveness of the registration statement for the issuer's initial public offering. Under the terms of the policy, the Reporting Person received an option to purchase 25,000 shares. Due to a clerical error, the original Form 4 filed on December 1, 2017 erroneously reported an option grant of 7,324 shares. This Amendment to Form 4 is filed solely to correct the share number."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option becomes exercisable as to 33.3333% of the shares underlying the award on the first anniversary of the date of grant, with the remainder vesting in equal monthly installments until the third anniversary of the date of grant, subject to the Reporting Person's continued service as a director through each applicable vesting date."}],"balance_after":25000,"derivative":{"exercise_price":10,"expiration_date":"2027-11-14","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001209191-18-016591","document":"doc4a.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1438226/000120919118016591/doc4a.xml","form_type":"4/A","original_submission_date":"2017-12-01"}},{"id":4146037,"issuer":{"id":5638,"kind":"organization","name":"X4 Pharmaceuticals, Inc","symbol":"XFOR"},"owners":[{"id":16563,"kind":"person","name":"SCHULMAN AMY W","position":1,"cik":"0001438226","reported_name":"SCHULMAN AMY W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2017-12-01T22:18:03.000Z","date":"2017-11-15","kind":"grant","acquired":true,"shares":7324,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Consists of an automatic stock option grant that was made on November 15, 2017, the date of the effectiveness of the registration statement for the issuer's initial public offering, under the issuer's director compensation program."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option becomes exercisable as to 33.3333% of the shares underlying the award on the first anniversary of the date of grant, with the remainder vesting in equal monthly installments until the third anniversary of the date of grant, subject to the Reporting Person's continued service as a director through each applicable vesting date."}],"balance_after":7324,"derivative":{"exercise_price":10,"expiration_date":"2027-11-14","underlying":"Common Stock","underlying_shares":7324},"source":{"system":"sec-edgar","filing":"0000899243-17-027822","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1438226/000089924317027822/doc4.xml","form_type":"4"}},{"id":4291302,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":16563,"kind":"person","name":"SCHULMAN AMY W","position":1,"cik":"0001438226","reported_name":"SCHULMAN AMY W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option  (right to buy)","published_at":"2017-06-06T21:01:15.000Z","date":"2017-06-02","kind":"grant","acquired":true,"shares":11250,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":11250,"derivative":{"exercise_price":71.99,"exercise_date":"2018-06-02","expiration_date":"2027-06-01","underlying":"Common Stock","underlying_shares":11250},"source":{"system":"sec-edgar","filing":"0001553878-17-000031","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000155387817000031/edgardoc.xml","form_type":"4"}}],"next_cursor":"2017-06-06T21:01:15.000000Z,4291302"}